Empagliflozin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Empagliflozin comprises 873 peer-reviewed publications across 15 journals, 25 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Heart Failure, Albuminuria, and Alzheimer Disease. Most recent publication: Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial., Am Heart J, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Rodriguez LA, Finertie H, Neugebauer RS, et al. · Lancet Reg Health Am · 2024
    PubMed: PMID 38745886 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
  2. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022
    PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  3. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025
    PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  4. Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025
    PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  5. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023
    PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  6. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023
    PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  7. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022
    PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  8. Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.
    Neugebauer R, An J, Dombrowski SK, et al. · JAMA Netw Open · 2025
    PubMed: PMID 41091469 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01719003Diabetes Mellitus, Type 2HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24
baseline and 24 weeks
Empagliflozin 10 mg qd-1.35 percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 12.5 mg Bid+ Metformin 1000 mg Bid-2.08 percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 12.5 mg Bid+ Metformin 500 mg Bid-1.93 percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 25 mg qd-1.36 percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 5 mg Bid + Metformin 1000 mg Bid-2.07 percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 5 mg Bid + Metformin 500 mg Bid-1.98 percentage of HbA1c (±0.08 Standard Error)
Metformin 1000 mg Bid-1.75 percentage of HbA1c (±0.09 Standard Error)
Metformin 500 mg Bid-1.18 percentage of HbA1c (±0.08 Standard Error)
NCT01734785Diabetes Mellitus, Type 2HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment
Baseline and 24 weeks
Empagliflozin 10 mg-0.65 Percentage of HbA1c (±0.08 Standard Error)
Empagliflozin 25 mg-0.56 Percentage of HbA1c (±0.08 Standard Error)
Placebo0.14 Percentage of HbA1c (±0.09 Standard Error)
NCT01947855Diabetes Mellitus, Type 2Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment
1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day -1 (baseline), and 1h, 1.5h, 2h, 2.5, 3h, 3.5h and 4h after drug administration at day 28
Empagliflozin 10 mg-103.56 mg*h/dL (±14.24 Standard Error)
Empagliflozin 25 mg-122.94 mg*h/dL (±14.35 Standard Error)
Placebo-18.07 mg*h/dL (±13.89 Standard Error)
NCT02182830Diabetes Mellitus, Type 2Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks
baseline and 24 weeks
Empagliflozin 10 Mg-25mg-0.71 percentage of glycated haemoglobin (±0.14 Standard Error)
Placebo0.07 percentage of glycated haemoglobin (±0.14 Standard Error)
NCT02414958Diabetes Mellitus, Type 1Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26
Baseline to week 26
Empagliflozin 10 mg-0.44 Percentage (%) (±0.04 Standard Error)
Empagliflozin 25 mg-0.44 Percentage (%) (±0.04 Standard Error)
Placebo Matching Empagliflozin0.09 Percentage (%) (±0.04 Standard Error)
NCT02414958Diabetes Mellitus, Type 1Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD) )
Baseline to week 26
Empagliflozin 10 mg-0.43 Percentage (%) (±0.04 Standard Error)
Empagliflozin 25 mg-0.42 Percentage (%) (±0.04 Standard Error)
Placebo Matching Empagliflozin0.09 Percentage (%) (±0.04 Standard Error)
NCT02453555Diabetes Mellitus, Type 2Change of Glycosylated Haemoglobin A1c (Glycosylated Haemoglobin A1c After 24 Weeks of Double-blind Treatment From Baseline)
Baseline and 24 week
Empagliflozin 10 mg/Linagliptin 5 mg-0.93 Percentage (%) (±0.06 Standard Error)
Linagliptin 5 mg + Placebo 10 mg0.21 Percentage (%) (±0.09 Standard Error)
NCT02489968Diabetes Mellitus, Type 2Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment
Baseline and 24 week
Empagliflozin 10 mg + Linagliptin 5 mg-0.94 Percentage (%) (±0.05 Standard Error)
Empagliflozin 10 mg + Placebo-0.12 Percentage (%) (±0.06 Standard Error)
Empagliflozin 25 mg + Linagliptin 5 mg-0.91 Percentage (%) (±0.05 Standard Error)
Empagliflozin 25 mg + Placebo-0.33 Percentage (%) (±0.05 Standard Error)
NCT02580591Diabetes Mellitus, Type 1Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Full Analysis Set (FAS) (Observed Cases [OC])
Baseline to week 26
Empagliflozin 10 mg-0.25 Percentage (%) (±0.05 Standard Error)
Empagliflozin 2.5 Milligram (mg)-0.09 Percentage (%) (±0.05 Standard Error)
Empagliflozin 25 mg-0.33 Percentage (%) (±0.05 Standard Error)
Placebo Matching Empagliflozin0.20 Percentage (%) (±0.05 Standard Error)
NCT02580591Diabetes Mellitus, Type 1Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 for Modified Intention-to-treat Population Set (mITT) (Observed Case (OC) - All Data (AD) (OC-AD))
Baseline to week 26
Empagliflozin 10 mg-0.23 Percentage (%) (±0.05 Standard Error)
Empagliflozin 2.5 Milligram (mg)-0.06 Percentage (%) (±0.05 Standard Error)
Empagliflozin 25 mg-0.30 Percentage (%) (±0.05 Standard Error)
Placebo Matching Empagliflozin0.21 Percentage (%) (±0.05 Standard Error)
NCT02863328
PIONEER 2
Diabetes Mellitus, Type 2Change in HbA1c
Week 0, week 26
Empagliflozin 25 mg-0.9 Percentage-point of HbA1c (±0.9 Standard Deviation)
Empagliflozin 25 mg-0.9 Percentage-point of HbA1c (±0.9 Standard Deviation)
Oral Semaglutide 14 mg-1.3 Percentage-point of HbA1c (±1.1 Standard Deviation)
Oral Semaglutide 14 mg-1.5 Percentage-point of HbA1c (±1.1 Standard Deviation)
NCT03057951Heart FailureTime to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
From randomization until completion of the planned treatment phase, up to 1403 days.
10 mg Empagliflozin6.86 Patients with event/100 pt-yrs at risk
Placebo8.67 Patients with event/100 pt-yrs at risk
NCT03057977Heart FailureTime to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
From randomisation until completion of the planned treatment period, up to 1040 days.
10 mg Empagliflozin15.77 Patients with events/ 100 pt-yrs at risk
Placebo21.00 Patients with events/ 100 pt-yrs at risk
NCT03087773
EMMY
Heart FailureChanges of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels
26 weeks
Empagliflozin-84.9 pg/mL
Placebo Oral Tablet-82.2 pg/mL
NCT03332212Heart FailureChange From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS).
At baseline and at week 12.
Empagliflozin 10mg Cohort A-0.179 PCr / ATP Ratio (±0.117 Standard Error)
Empagliflozin 10mg Cohort B0.100 PCr / ATP Ratio (±0.143 Standard Error)
Placebo Cohort A0.068 PCr / ATP Ratio (±0.114 Standard Error)
Placebo Cohort B0.259 PCr / ATP Ratio (±0.156 Standard Error)
NCT03351478
SOTA-EMPA
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26
Baseline, Week 26
Empagliflozin 25 mg-0.8 percentage of HbA1c (±0.1 Standard Error)
Placebo-0.3 percentage of HbA1c (±0.1 Standard Error)
Sotagliflozin 400 mg-0.7 percentage of HbA1c (±0.1 Standard Error)
NCT03429543Diabetes Mellitus, Type 2Change in Glycated Haemoglobin (HbA1c) (%) From Baseline to the End of 26 Weeks - DINAMOᵀᴹ
Baseline (Day 1) and week 26 of treatment.
Empagliflozin 10 mg - DINAMOᵀᴹ & Empagliflozin 10 - 25 mg - DINAMOᵀᴹ (TG2)0.14 Percent change
Empagliflozin 10 mg - DINAMOᵀᴹ (TG3)-0.49 Percent change
Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ (TG1)-0.17 Percent change
Linagliptin 5 mg - DINAMOᵀᴹ (TG1)0.33 Percent change
Placebo - DINAMOᵀᴹ (TG1, TG2 & TG3)NA Percent change
NCT03429543Diabetes Mellitus, Type 2Percentage of Patients With Treatment Failure up to or at Week 26
Up to 26 weeks.
Empagliflozin Pooled (10 mg and 25 mg) - DINAMOᵀᴹ Mono50.0 Percentage of subjects
Linagliptin 5 mg - DINAMOᵀᴹ Mono50.0 Percentage of subjects
Placebo - DINAMOᵀᴹ Mono60.0 Percentage of subjects
NCT03448406Heart FailureChange From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD)
At baseline and at Week 12
10 mg Empagliflozin10.0 Meter (m)
Placebo5.0 Meter (m)
NCT03448419Heart FailureChange From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance
At baseline and at week 12
10 mg Empagliflozin13.5 Meter (m)
Placebo18.0 Meter (m)
NCT03594110Renal Insufficiency, ChronicInterventional Part: Time to First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')
From the day of randomisation to the day of the final follow-up visit in the interventional part of the trial, up to 1136 days.
Empagliflozin 10 mg6.85 patients with events/100 pt-yrs at risk
Placebo8.96 patients with events/100 pt-yrs at risk
NCT03594110Renal Insufficiency, ChronicOverall Study: Time to the First Occurrence of Kidney Disease Progression or Cardiovascular Death ('as Adjudicated')
From the day of randomization in the interventional part of the trial until the individual day of end of study in the non-interventional part of the trial. Up to 1869 days.
Empagliflozin 10 mg8.36 patients with events/100 pt-yrs at risk
Placebo9.99 patients with events/100 pt-yrs at risk
NCT04157751Heart FailurePercentage of Pairwise Comparisons With Wins of Clinical Benefit, a Composite of Death, Number of Heart Failure Events (HFEs), Time to the First HFE and ≥5-point Difference in CfB in KCCQ-TSS After 90 Days of Treatment
Up to 90 days. For KCCQ-TSS: at baseline and at day 90.
10 mg Empagliflozin7.15 pct. (%) of winning pairwise comparisons
10 mg Empagliflozin10.59 pct. (%) of winning pairwise comparisons
10 mg Empagliflozin0.24 pct. (%) of winning pairwise comparisons
10 mg Empagliflozin35.91 pct. (%) of winning pairwise comparisons
Placebo4.01 pct. (%) of winning pairwise comparisons
Placebo7.65 pct. (%) of winning pairwise comparisons
Placebo27.48 pct. (%) of winning pairwise comparisons
Placebo0.57 pct. (%) of winning pairwise comparisons
NCT04233801Diabetes Mellitus, Type 2Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24
At baseline (Week 0) and at Week 24
Empagliflozin 10 mg-1.12 Percentage of glycosylated hemoglobin (±0.10 Standard Error)
Empagliflozin 25 mg-1.12 Percentage of glycosylated hemoglobin (±0.10 Standard Error)
Placebo-0.13 Percentage of glycosylated hemoglobin (±0.10 Standard Error)
NCT04509674Myocardial InfarctionComposite of Time to First Heart Failure Hospitalisation or All-cause Mortality
From randomisation or first study drug administration (if randomisation occurred after first drug administration), until individual day of trial completion. Up to 1004 days.
Empagliflozin 10 mg5.85 Pt with events/100 pt-years at risk
Placebo6.58 Pt with events/100 pt-years at risk

Publications by year

1969–2026: 873 publications.

1969
1
1972
1
1977
1
1979
2
1982
3
1985
2
1986
2
1987
1
1988
3
1990
2
1991
2
1992
3
1993
1
1994
3
1995
2
1996
3
1997
10
1998
10
1999
4
2000
2
2001
9
2002
12
2003
5
2004
8
2005
11
2006
16
2007
8
2008
17
2009
17
2010
16
2011
25
2012
15
2013
17
2014
36
2015
30
2016
26
2017
37
2018
32
2019
49
2020
79
2021
95
2022
100
2023
56
2024
47
2025
36
2026
16

Publications by indication

Diabetes Mellitus, Type 2 (233)

  • Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    J Am Soc Nephrol · 2026 · PMID 41196655 · NCT05254002
  • Variability in muscle function deficits and clinical identification of sarcopenic obesity in older adults with type 2 diabetes.
    Front Med (Lausanne) · 2026 · PMID 41789181 · NCT03560375
  • Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
    J Am Coll Cardiol · 2026 · PMID 41493296 · NCT05254002
  • Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
    Clin J Am Soc Nephrol · 2026 · PMID 40965042 · NCT05254002
  • Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
    J Am Soc Nephrol · 2026 · PMID 41905767 · NCT05254002

Heart Failure (108)

  • Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.
    Am J Cardiovasc Drugs · 2026 · PMID 40855136 · NCT06249945
  • Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    J Am Soc Nephrol · 2026 · PMID 40526444 · NCT04157751
  • Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-Preserved.
    JACC Heart Fail · 2026 · PMID 41493412 · NCT03057951
  • Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.
    JACC Heart Fail · 2026 · PMID 41793401 · NCT04157751
  • Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.
    Clin Res Cardiol · 2025 · PMID 39297940 · NCT03087773

Albuminuria (88)

  • Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model.
    J Cell Mol Med · 2024 · PMID 39267208 · NCT07175051
  • SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback.
    Kidney360 · 2024 · PMID 38523127 · NCT07175051
  • GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
    Am J Hematol · 2024 · PMID 38655752 · NCT07175051
  • Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors.
    J Clin Invest · 2023 · PMID 36856116 · NCT07175051
  • Dapagliflozin in people with chronic kidney disease.
    Drug Ther Bull · 2023 · PMID 37257897 · NCT07175051

Alzheimer Disease (53)

  • A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.
    Alzheimers Dement · 2025 · PMID 41057918 · NCT05081219
  • Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks.
    Behav Sleep Med · 2012 · PMID 22250775 · NCT05081219
  • Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Arch Neurol · 2012 · PMID 21911655 · NCT05081219
  • The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Alzheimers Dement · 2012 · PMID 21514249 · NCT05081219
  • Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.
    Alzheimer Dis Assoc Disord · 2011 · PMID 20921876 · NCT05081219

Diabetes Mellitus, Type 1 (39)

  • Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
    Diabetes Obes Metab · 2024 · PMID 34989070 · NCT06894784
  • Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes.
    Diabetes Care · 2023 · PMID 37616393 · NCT02414958
  • Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
    Diabetes Obes Metab · 2023 · PMID 36942888 · NCT06894784
  • Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes.
    Diabetes Technol Ther · 2022 · PMID 35255229 · NCT04201496
  • Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.
    Diabetes Care · 2022 · PMID 36331522 · NCT06894784

Non-alcoholic Fatty Liver Disease (38)

  • Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.
    J Taibah Univ Med Sci · 2025 · PMID 40823521 · NCT05694923
  • Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    J Magn Reson Imaging · 2025 · PMID 22025886 · NCT02686476
  • Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Hepatology · 2024 · PMID 38536017 · NCT04642261
  • The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment.
    Hepatol Res · 2024 · PMID 26785389 · NCT02964715
  • Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Front Endocrinol (Lausanne) · 2022 · PMID 35282455 · NCT05605158

Publications by journal

Trial-results highlights

In studies for Type 2 Diabetes Mellitus, the drug Empagliflozin demonstrated effects on HbA1c levels. In NCT01719003, the mean change from baseline in HbA1c at Week 24 was -1.35 percentage of HbA1c for the Empagliflozin 10 mg qd arm and -1.36 percentage of HbA1c for the Empagliflozin 25 mg qd arm. When combined with metformin, the mean changes were:

  • Empagliflozin 12.5 mg Bid + Metformin 1000 mg Bid: -2.08 percentage of HbA1c
  • Empagliflozin 5 mg Bid + Metformin 1000 mg Bid: -2.07 percentage of HbA1c
  • Empagliflozin 12.5 mg Bid + Metformin 500 mg Bid: -1.93 percentage of HbA1c
  • Empagliflozin 5 mg Bid + Metformin 500 mg Bid: -1.98 percentage of HbA1c

In NCT01734785, the least squares mean change in HbA1c after 24 weeks was -0.65 Percentage of HbA1c for the Empagliflozin 10 mg arm and -0.56 Percentage of HbA1c for the Empagliflozin 25 mg arm, compared to 0.14 Percentage of HbA1c for the Placebo arm. In NCT02182830, the Empagliflozin 10 Mg-25mg arm showed a mean change of -0.71 percentage of glycated haemoglobin at 24 weeks, versus 0.07 percentage of glycated haemoglobin for the Placebo arm. For postprandial plasma glucose, NCT01947855 reported a least squares mean change in AUC1-4h after 28 days of -122.94 mg*h/dL for the Empagliflozin 25 mg arm and -103.56 mg*h/dL for the Empagliflozin 10 mg arm, versus -18.07 mg*h/dL for the Placebo arm. In combination with linagliptin, NCT02453555 reported a least squares mean change of -0.93 Percentage (%) for the Empagliflozin 10 mg/Linagliptin 5 mg arm after 24 weeks. In NCT02489968, the Empagliflozin 10 mg + Linagliptin 5 mg arm showed a least squares mean change of -0.94 Percentage (%), and the Empagliflozin 25 mg + Linagliptin 5 mg arm showed -0.91 Percentage (%).

For Type 1 Diabetes Mellitus, NCT02414958 assessed the change from baseline in HbA1c at Week 26. The Empagliflozin 10 mg arm reported a least squares mean change of -0.44 Percentage (%), and the Empagliflozin 25 mg arm also reported -0.44 Percentage (%). The Placebo Matching Empagliflozin arm showed 0.09 Percentage (%). For the modified intention-to-treat population in the same study, the Empagliflozin 10 mg arm showed a least squares mean change of -0.43 Percentage (%), and the Empagliflozin 25 mg arm showed -0.42 Percentage (%), compared to 0.09 Percentage (%) for the Placebo Matching Empagliflozin arm.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Empagliflozin publications (873)

2026 (16 papers)

  1. Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial.
    Sørensen LM, Reinert MS, Raja AA, et al. · Am Heart J · 2026 · Derived
    PubMed: PMID 41903746 · NCT06171802 (EMPAVR) · Aortic Valve Stenosis
  2. Effects of Empagliflozin on Right Ventricular Function in Heart Failure with Reduced Ejection Fraction.
    Omar M, Jensen J, Frederiksen PH, et al. · medRxiv · 2026 · Derived
    PubMed: PMID 40502611 · NCT03198585 (Empire HF)
  3. Effects of Empagliflozin on Right Ventricular Free-Wall Strain in Patients with Heart Failure and Reduced Ejection Fraction.
    Omar M, Jensen J, Ali M, et al. · ESC Heart Fail · 2026 · Derived
    PubMed: PMID 41711194 · NCT03198585 (Empire HF)
  4. Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
    Mottl A, Scott C, Green JB, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41196655 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  5. Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.
    Mahboub BM, Refaie AF, El-Haggar SM, et al. · Diabetol Metab Syndr · 2026 · Derived
    PubMed: PMID 41373013 · NCT05373680 · Renal Insufficiency, Chronic
  6. A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.
    Liu H, Zhang Y, Feng L, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 42014686 · NCT03790787
  7. Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease.
    Lin DS, Lo HY, Yang CW, et al. · Am J Cardiovasc Drugs · 2026 · Derived
    PubMed: PMID 40855136 · NCT06249945 (EMPA-PRED) · Heart Failure
  8. Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point.
    Jongs N, Gasparyan SB, Frison L, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40526444 · NCT04157751 · Heart Failure
  9. Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD.
    Gashaw IA, Tuttle KR, Monroy Kuhn M, et al. · Eur J Endocrinol · 2026 · Derived
    PubMed: PMID 41436034 · NCT05182840 · Renal Insufficiency, Chronic
  10. Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-Preserved.
    Ferreira JP, Packer M, Butler J, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 41493412 · NCT03057951 · Heart Failure
  11. Short- and mid-term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure.
    Bytyqi V, Kannenkeril D, Kolwelter J, et al. · Eur J Heart Fail · 2026 · Derived
    PubMed: PMID 41186108 · NCT03128528 (ELSI)
  12. Variability in muscle function deficits and clinical identification of sarcopenic obesity in older adults with type 2 diabetes.
    Barak S, Eldor R, Dotan I, et al. · Front Med (Lausanne) · 2026 · Derived
    PubMed: PMID 41789181 · NCT03560375 · Diabetes Mellitus, Type 2
  13. Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.
    Angermann CE, Gerhardt T, Blatchford JP, et al. · JACC Heart Fail · 2026 · Derived
    PubMed: PMID 41793401 · NCT04157751 · Heart Failure
  14. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
    Agarwal R, Green JB, Heerspink HJL, et al. · J Am Coll Cardiol · 2026 · Derived
    PubMed: PMID 41493296 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  15. Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
    Agarwal R, Green JB, Heerspink HJL, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 40965042 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  16. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
    Agarwal R, Correa-Rotter R, Navaneethan SD, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41905767 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2

2025 (36 papers)

  1. Clinical and Demographic Characteristics Associated With Diabetes Remission in Six Integrated Health Care Systems: A Retrospective Cohort Study.
    Thapa B, Schmittdiel JA, Arterburn D, et al. · Diabetes Care · 2025 · Trial result
    PubMed: PMID 40734551 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
  2. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
    PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  3. Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
    PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  4. Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes.
    Neugebauer R, An J, Dombrowski SK, et al. · JAMA Netw Open · 2025 · Trial result
    PubMed: PMID 41091469 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
  5. Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
    Zhou J, Williams C, Staplin N, et al. · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 40686671 · NCT03594110 · Renal Insufficiency, Chronic
  6. Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.
    Yu C, Yang H, Zhang B, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 40840993 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
  7. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
    Vaduganathan M, Green JB, Heerspink HJL, et al. · Nephrol Dial Transplant · 2025 · Derived
    PubMed: PMID 40886054 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  8. Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial.
    Uster A, Desai N, Navaneethan SD, et al. · Clin Ther · 2025 · Derived
    PubMed: PMID 41047325 · NCT03594110 · Renal Insufficiency, Chronic
  9. Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.
    Taha BO, Kobeisy MA, Abdelmohsen E, et al. · J Taibah Univ Med Sci · 2025 · Derived
    PubMed: PMID 40823521 · NCT05694923 (Fatty liver) · Non-alcoholic Fatty Liver Disease
  10. Effect of empagliflozin on reducing the no-reflow phenomenon in patients with ST-elevation myocardial infarction: rationale and design of the EMPA-PCI trial.
    Solis-Jimenez F, Araiza-Garaygordobil D, Masso-Bueso JS, et al. · Eur Heart J Open · 2025 · Derived
    PubMed: PMID 41230400 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  11. Comparative effects of empagliflozin and metformin on metabolic dysfunction in polycystic ovary syndrome, a double blinded randomized control feasibility trial.
    Sharif H, Arsalan S, Rehman N, et al. · BMC Womens Health · 2025 · Derived
    PubMed: PMID 41257673 · NCT06140108 · Polycystic Ovary Syndrome
  12. Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial.
    Schwegel N, Strohhofer C, Kolesnik E, et al. · Clin Res Cardiol · 2025 · Derived
    PubMed: PMID 39297940 · NCT03087773 (EMMY) · Heart Failure
  13. Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial.
    Rizk MA, El-Haggar SM, Ibrahim OM, et al. · J Diabetes Complications · 2025 · Derived
    PubMed: PMID 40946347 · NCT05638880 · Diabetic Nephropathies
  14. Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin.
    Requena-Ibáñez JA, Zafar MU, Ferrandez-Escarabajal M, et al. · J Cardiovasc Pharmacol · 2025 · Derived
    PubMed: PMID 40748666 · NCT06618976 (SOTATHROMBUS) · Heart Failure
  15. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 40036152 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  16. Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.
    Ovchinnikov A, Potekhina A, Filatova A, et al. · Cardiovasc Diabetol · 2025 · Derived
    PubMed: PMID 40346546 · NCT03753087 · Diabetes Mellitus, Type 2
  17. Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.
    Oshima M, Buizen L, Jongs N, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40658498 · NCT03594110 · Renal Insufficiency, Chronic
  18. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.
    Natale P, Green SC, Tunnicliffe DJ, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 39963952 · NCT04061200 (EmpaSema)
  19. Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.
    Murugavel S, Retnakaran R, Feig DS, et al. · Diabetes Obes Metab · 2025 · Derived
    PubMed: PMID 40964955 · NCT03215069 (EMPA post-GDM) · Diabetes, Gestational
  20. Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
    Mayne KJ, Sardell RJ, Staplin N, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40179340 · NCT03594110 · Renal Insufficiency, Chronic
  21. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.
    Lee M, Hong S, Cho Y, et al. · BMC Med · 2025 · Derived
    PubMed: PMID 40336058 · NCT03646292 · Diabetes Mellitus, Type 2
  22. Sodium-Glucose Cotransporter-2 Inhibitor Therapy and Longitudinal Changes in Kidney Function among Veterans with Autosomal Dominant Polycystic Kidney Disease.
    Eswarappa M, Madden E, Shlipak MG, et al. · Clin J Am Soc Nephrol · 2025 · Derived
    PubMed: PMID 40377984 · NCT05510115 · Polycystic Kidney, Autosomal Dominant
  23. A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.
    Erichsen JM, Register TC, Sutphen C, et al. · Alzheimers Dement · 2025 · Derived
    PubMed: PMID 41057918 · NCT05081219 · Alzheimer Disease
  24. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
    EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 39453837 · NCT03594110 · Renal Insufficiency, Chronic
  25. Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Patients With Coronary Heart Disease and Heart Failure Treated With Empagliflozin.
    El-Sherbeni AA, Khedr NF, Khairat I, et al. · Clin Ther · 2025 · Derived
    PubMed: PMID 40413121 · NCT05911724 · Heart Failure
  26. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial.
    Carson P, Teerlink JR, Komajda M, et al. · JACC Heart Fail · 2025 · Derived
    PubMed: PMID 39895437 · NCT03057951 · Heart Failure
  27. Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial.
    Bauer KI, Baker D, Lerner R, et al. · Cardiovasc Diabetol · 2025 · Derived
    PubMed: PMID 40922034 · NCT02932436 (EmDia) · Diabetes Mellitus, Type 2
  28. Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.
    Angermann CE, Sehner S, Gerhardt LMS, et al. · Eur Heart J · 2025 · Derived
    PubMed: PMID 39907687 · NCT03485222 (EMPA-TROPISM) · Heart Failure
  29. Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial.
    Anderegg MA, Schietzel S, Bargagli M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 39747681 · NCT04911660 (SWEETSTONE) · Kidney Calculi
  30. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
    Agarwal R, Green JB, Heerspink HJL, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40470996 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  31. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
    Agarwal R, Green JB, Heerspink HJL, et al. · Nephrol Dial Transplant · 2025 · Derived
    PubMed: PMID 39916475 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  32. Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy.
    Reeder SB, Cruite I, Hamilton G, et al. · J Magn Reson Imaging · 2025 · Background
    PubMed: PMID 22025886 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  33. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group.
    Kossoff EH, Zupec-Kania BA, Auvin S, et al. · Epilepsia Open · 2025 · Background
    PubMed: PMID 29881797 · NCT05512130 · Epilepsy
  34. Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus.
    Khan F, Hussain T, Chaudhry TZ, et al. · Cureus · 2025 · Background
    PubMed: PMID 39723311 · NCT07452913 · Diabetes Mellitus, Type 2
  35. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.
    Joshi SS, Singh T, Newby DE, et al. · Heart · 2025 · Background
    PubMed: PMID 33637556 · NCT06012266 · Heart Failure
  36. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.
    Bozkurt B, Coats AJ, Tsutsui H, et al. · J Card Fail · 2025 · Background
    PubMed: PMID 33663906 · NCT05129722

2024 (47 papers)

  1. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
    Sourij C, Oulhaj A, Aziz F, et al. · Diabetes Obes Metab · 2024 · Trial result
    PubMed: PMID 38287198 · NCT03087773 (EMMY) · Heart Failure
  2. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial.
    Sourij C, Aziz F, Tripolt NJ, et al. · Hellenic J Cardiol · 2024 · Trial result
    PubMed: PMID 37236318 · NCT03087773 (EMMY) · Heart Failure
  3. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Rodriguez LA, Finertie H, Neugebauer RS, et al. · Lancet Reg Health Am · 2024 · Trial result
    PubMed: PMID 38745886 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
  4. Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group, Horby PW, Peto L, et al. · Nat Commun · 2024 · Trial result
    PubMed: PMID 38296965 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  5. Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease.
    Zachariah T, Radhakrishnan J · Clin J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39037799 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  6. Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial.
    Yuan T, Liu S, Dong Y, et al. · Diabetol Metab Syndr · 2024 · Derived
    PubMed: PMID 33117454 · NCT04014192 · Diabetes Mellitus, Type 2
  7. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
    Udell JA, Petrie MC, Jones WS, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 38588929 · NCT04509674 · Myocardial Infarction
  8. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
    Tuttle KR, Hauske SJ, Canziani ME, et al. · Lancet · 2024 · Derived
    PubMed: PMID 38109916 · NCT05182840 · Renal Insufficiency, Chronic
  9. Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
    St Pierre K, Cashmore BA, Bolignano D, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 39356039 · NCT06435858 (SIDIA) · Polycystic Kidney, Autosomal Dominant
  10. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
    Rossing P · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39078403 · NCT05254002 (CONFIDENCE) · Diabetes Mellitus, Type 2
  11. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Child Adolesc Health · 2024 · Derived
    PubMed: PMID 38272046 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  12. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
    Rao VS, Ivey-Miranda JB, Cox ZL, et al. · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 38073038 · NCT03027960 (EMPA) · Diabetes Mellitus, Type 2
  13. Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
    Pourafkari M, Connelly KA, Verma S, et al. · Cardiovasc Diabetol · 2024 · Derived
    PubMed: PMID 39198860 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  14. Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
    Pessoa-Amorim G, Goldacre R, Crichton C, et al. · Trials · 2024 · Derived
    PubMed: PMID 38951929 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  15. Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.
    Packer M, Ferreira JP, Butler J, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 39217550 · NCT03057977 · Heart Failure
  16. Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease.
    Oh M, Choi JH, Kim SO, et al. · Nucl Med Commun · 2024 · Derived
    PubMed: PMID 34397987 · NCT03208465 (ELITE) · Diabetes Mellitus
  17. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P, Tunnicliffe DJ, Toyama T, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38770818 · NCT03057977 · Heart Failure
  18. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
    Natale P, Palmer SC, Navaneethan SD, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38682786 · NCT04238702 (RECOLAR) · Diabetes Mellitus, Type 2
  19. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
    Mayne KJ, Staplin N, Keane DF, et al. · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 38082486 · NCT03594110 · Renal Insufficiency, Chronic
  20. A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).
    Hirota Y, Kakei Y, Imai J, et al. · Diabetes Ther · 2024 · Derived
    PubMed: PMID 38216831 · NCT04018365 (EMPIRE-01) · Diabetes Mellitus
  21. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial.
    Hernandez AF, Udell JA, Jones WS, et al. · Circulation · 2024 · Derived
    PubMed: PMID 38581389 · NCT04509674 · Myocardial Infarction
  22. Is GFR decline induced by SGLT2 inhibitor of clinical importance?
    Günes-Altan M, Bosch A, Striepe K, et al. · Cardiovasc Diabetol · 2024 · Derived
    PubMed: PMID 38811998 · NCT02752113 (ELMI) · Diabetes Mellitus, Type 2
  23. Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme.
    Ferreira JP, Packer M, Sattar N, et al. · Eur J Heart Fail · 2024 · Derived
    PubMed: PMID 38439582 · NCT03057951 · Heart Failure
  24. Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus.
    El-Haggar SM, Hafez YM, El Sharkawy AM, et al. · Med Clin (Barc) · 2024 · Derived
    PubMed: PMID 38653618 · NCT05977465
  25. Metformin for preventing the progression of chronic kidney disease.
    El-Damanawi R, Stanley IK, Staatz C, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38837240 · NCT05373680 · Renal Insufficiency, Chronic
  26. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    Edmonston D, Mulder H, Lydon E, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 39142723 · NCT05465317 · Diabetes Mellitus, Type 2
  27. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.
    Dhingra NK, Verma S, Butler J, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 37715769 · NCT03057977 · Heart Failure
  28. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Cheung KS, Ng HY, Hui RWH, et al. · Hepatology · 2024 · Derived
    PubMed: PMID 38536017 · NCT04642261 · Non-alcoholic Fatty Liver Disease
  29. Empagliflozin after Acute Myocardial Infarction.
    Butler J, Jones WS, Udell JA, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38587237 · NCT04509674 · Myocardial Infarction
  30. Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial.
    Bahlmann-Kroll E, Häckl S, Kramer S, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 39675824 · NCT06391450 (EMPA-PKD) · Polycystic Kidney, Autosomal Dominant
  31. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure.
    Angermann CE, Santos-Gallego CG, Requena-Ibanez JA, et al. · Nat Cardiovasc Res · 2024 · Derived
    PubMed: PMID 39196095 · NCT03485222 (EMPA-TROPISM) · Heart Failure
  32. Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program.
    Andersen CF, Larsen JH, Jensen J, et al. · Am Heart J · 2024 · Derived
    PubMed: PMID 38365073 · NCT05084235 · Heart Failure
  33. The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang X, Tong WK, Xia Q, et al. · Qual Life Res · 2024 · Background
    PubMed: PMID 39096426 · NCT07452913 · Diabetes Mellitus, Type 2
  34. Inhibition of sodium-glucose cotransporter-2 improves anaemia in mice and humans with sickle cell disease, and reduces infarct size in a murine stroke model.
    Wang J, Silaghi P, Guo C, et al. · J Cell Mol Med · 2024 · Background
    PubMed: PMID 39267208 · NCT07175051 (EMPA-CKD) · Albuminuria
  35. SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback.
    Upadhyay A · Kidney360 · 2024 · Background
    PubMed: PMID 38523127 · NCT07175051 (EMPA-CKD) · Albuminuria
  36. Principles for Stakeholder Engagement in Observational Health Research.
    Thomas TW, Hooker SA, Schmittdiel JA, et al. · JAMA Health Forum · 2024 · Background
    PubMed: PMID 38488777 · NCT05073692 (ON TARGET DM) · Diabetes Mellitus, Type 2
  37. GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
    Sun R, Srivastava A, Derebail VK, et al. · Am J Hematol · 2024 · Background
    PubMed: PMID 38655752 · NCT07175051 (EMPA-CKD) · Albuminuria
  38. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.
    Lu X, Xie Q, Pan X, et al. · Signal Transduct Target Ther · 2024 · Background
    PubMed: PMID 39353925 · NCT07452913 · Diabetes Mellitus, Type 2
  39. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study.
    Lean ME, Leslie WS, Barnes AC, et al. · Lancet Diabetes Endocrinol · 2024 · Background
    PubMed: PMID 38423026 · NCT07452913 · Diabetes Mellitus, Type 2
  40. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review.
    Lava SAG, Laurence C, Di Deo A, et al. · Paediatr Drugs · 2024 · Background
    PubMed: PMID 38635113 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  41. Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
    Kobayati A, Haidar A, Tsoukas MA, et al. · Diabetes Obes Metab · 2024 · Background
    PubMed: PMID 34989070 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  42. A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).
    Kim HJ, Noh JH, Moon MK, et al. · J Diabetes Res · 2024 · Background
    PubMed: PMID 38223523 · NCT06759922 · Diabetes Mellitus, Type 2
  43. The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors.
    Katsimardou A, Theofilis P, Vordoni A, et al. · Int J Mol Sci · 2024 · Background
    PubMed: PMID 39596449 · NCT07452913 · Diabetes Mellitus, Type 2
  44. Protective effects of empagliflozin on methotrexate induced hepatotoxicity in rats.
    Kalantari E, Zolbanin NM, Ghasemnejad-Berenji M, et al. · Biomed Pharmacother · 2024 · Background
    PubMed: PMID 38064971 · NCT06641128 · Arthritis, Rheumatoid
  45. Impact of very low carbohydrate ketogenic diets on cardiovascular risk factors among patients with type 2 diabetes; GRADE-assessed systematic review and meta-analysis of clinical trials.
    Ghasemi P, Jafari M, Maskouni SJ, et al. · Nutr Metab (Lond) · 2024 · Background
    PubMed: PMID 39030553 · NCT07452913 · Diabetes Mellitus, Type 2
  46. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment.
    Ballestri S, Nascimbeni F, Romagnoli D, et al. · Hepatol Res · 2024 · Background
    PubMed: PMID 26785389 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  47. "No-Reflow" Phenomenon: A Contemporary Review.
    Annibali G, Scrocca I, Aranzulla TC, et al. · J Clin Med · 2024 · Background
    PubMed: PMID 35456326 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon

2023 (56 papers)

  1. Timing of SGLT2i initiation after acute myocardial infarction.
    von Lewinski D, Kolesnik E, Aziz F, et al. · Cardiovasc Diabetol · 2023 · Trial result
    PubMed: PMID 37777743 · NCT03087773 (EMMY) · Heart Failure
  2. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023 · Trial result
    PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  3. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023 · Trial result
    PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  4. Dapagliflozin for inpatient hyperglycemia in cardiac surgery patients with type 2 diabetes: randomised controlled trial (Dapa-Hospital trial).
    Kuchay MS, Khatana P, Mishra M, et al. · Acta Diabetol · 2023 · Trial result
    PubMed: PMID 37380728 · NCT06187285 · Diabetes Mellitus, Type 2
  5. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.
    Benedikt M, Mangge H, Aziz F, et al. · Cardiovasc Diabetol · 2023 · Trial result
    PubMed: PMID 37407956 · NCT03087773 (EMMY) · Heart Failure
  6. Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.
    Aziz F, Tripolt NJ, Pferschy PN, et al. · Cardiovasc Diabetol · 2023 · Trial result
    PubMed: PMID 37475009 · NCT03087773 (EMMY) · Heart Failure
  7. Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved study.
    Zannad F, Macari S · Future Cardiol · 2023 · Derived
    PubMed: PMID 37942723 · NCT03057951 · Heart Failure
  8. Drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction: plain language summary of the EMPEROR-Reduced study.
    Zannad F, Macari S · Future Cardiol · 2023 · Derived
    PubMed: PMID 37942680 · NCT03057977 · Heart Failure
  9. Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced.
    Zannad F, Ferreira JP, Gregson J, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 35711093 · NCT03057977 · Heart Failure
  10. Empagliflozin in Patients with Chronic Kidney Disease.
    The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 36331190 · NCT03594110 · Renal Insufficiency, Chronic
  11. Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis.
    Staef M, Ott C, Kannenkeril D, et al. · Sci Rep · 2023 · Derived
    PubMed: PMID 37268640 · NCT02752113 (ELMI) · Diabetes Mellitus, Type 2
  12. Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes.
    Song C, Dhaliwal S, Bapat P, et al. · Diabetes Care · 2023 · Derived
    PubMed: PMID 37616393 · NCT02414958 · Diabetes Mellitus, Type 1
  13. Is increased myocardial triglyceride content associated with early changes in left ventricular function? A 1H-MRS and MRI strain study.
    Soghomonian A, Dutour A, Kachenoura N, et al. · Front Endocrinol (Lausanne) · 2023 · Derived
    PubMed: PMID 37424866 · NCT03118336 (EMPACEF) · Diabetes Mellitus, Type 2
  14. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Schulze PC, Bogoviku J, Westphal J, et al. · Circulation · 2023 · Derived
    PubMed: PMID 35766022 · NCT04049045 (EMPAG-HF)
  15. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis.
    Reiberger T, Berzigotti A, Trebicka J, et al. · Trials · 2023 · Derived
    PubMed: PMID 37095557 · NCT05282121 · Liver Diseases
  16. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
    Refardt J, Imber C, Nobbenhuis R, et al. · J Am Soc Nephrol · 2023 · Derived
    PubMed: PMID 36396331 · NCT03202667 (SANDx) · Hyponatremia
  17. Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study.
    Pulleyblank R, Larsen NB · Pharmacoecon Open · 2023 · Derived
    PubMed: PMID 37178435 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  18. The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
    Puar P, Ahmed S, Hibino M, et al. · Diabetes Obes Metab · 2023 · Derived
    PubMed: PMID 37246798 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  19. Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial.
    Prochaska JH, Jünger C, Schulz A, et al. · Clin Res Cardiol · 2023 · Derived
    PubMed: PMID 36763159 · NCT02932436 (EmDia) · Diabetes Mellitus, Type 2
  20. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Packer M, Butler J, Zeller C, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37621153 · NCT03057951 · Heart Failure
  21. An Increase in Plasma Sodium Levels Is Associated With an Increase in Osteoblast Function in Chronic SIAD.
    Monnerat S, Refardt J, Potasso L, et al. · J Clin Endocrinol Metab · 2023 · Derived
    PubMed: PMID 37098131 · NCT03202667 (SANDx) · Hyponatremia
  22. Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials.
    Larsen EL, Andersen A, Kjær LK, et al. · Free Radic Res · 2023 · Derived
    PubMed: PMID 37171199 · NCT02890745 (EMPOX) · Diabetes Mellitus, Type 2
  23. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
    Laffel LM, Danne T, Klingensmith GJ, et al. · Lancet Diabetes Endocrinol · 2023 · Derived
    PubMed: PMID 36738751 · NCT03429543 · Diabetes Mellitus, Type 2
  24. Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study.
    Ku EJ, Oh TK · Diabetes Ther · 2023 · Derived
    PubMed: PMID 37369826 · NCT05103306 (LUCID) · Diabetes Mellitus, Type 2
  25. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial.
    Kolwelter J, Kannenkeril D, Linz P, et al. · Clin Res Cardiol · 2023 · Derived
    PubMed: PMID 36289063 · NCT03128528 (ELSI)
  26. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.
    Khan MS, Butler J, Anker SD, et al. · J Am Heart Assoc · 2023 · Derived
    PubMed: PMID 36565199 · NCT03057977 · Heart Failure
  27. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
    Kario K, Okada K, Kato M, et al. · Circulation · 2023 · Derived
    PubMed: PMID 30586745 · NCT03050229 · Diabetes Mellitus, Type 2
  28. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37162745 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  29. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 36734509 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  30. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
    Hundertmark MJ, Adler A, Antoniades C, et al. · Circulation · 2023 · Derived
    PubMed: PMID 37070436 · NCT03332212 · Heart Failure
  31. Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease.
    Hogan MC, Simmons K, Ullman L, et al. · Kidney360 · 2023 · Derived
    PubMed: PMID 38010035 · NCT05510115 · Polycystic Kidney, Autosomal Dominant
  32. Antiplatelet agents for the treatment of adults with COVID-19.
    Fischer AL, Messer S, Riera R, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37489818 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  33. Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
    Ferreira JP, Blatchford JP, Teerlink JR, et al. · Eur J Heart Fail · 2023 · Derived
    PubMed: PMID 37540060 · NCT04157751 · Heart Failure
  34. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.
    Ferreira A, Schönenberger KA, Potoczna N, et al. · Diabetes Technol Ther · 2023 · Derived
    PubMed: PMID 37093196 · NCT05057819 · Hypoglycemia
  35. The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study.
    Feitosa MPM, Lima EG, Abizaid AAC, et al. · Diabetol Metab Syndr · 2023 · Derived
    PubMed: PMID 37365618 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  36. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
    EMPA-KIDNEY Collaborative Group · Lancet Diabetes Endocrinol · 2023 · Derived
    PubMed: PMID 38061372 · NCT03594110 · Renal Insufficiency, Chronic
  37. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group · Lancet Diabetes Endocrinol · 2023 · Derived
    PubMed: PMID 38061371 · NCT03594110 · Renal Insufficiency, Chronic
  38. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA, Mazer CD, Puar P, et al. · Circulation · 2023 · Derived
    PubMed: PMID 36335517 · NCT04461041 (EMPA-HEART 2) · Cardiovascular Diseases
  39. Challenges of using external data in clinical trials- an illustration in patients with COVID-19.
    Chevret S, Timsit JF, Biard L, et al. · BMC Med Res Methodol · 2023 · Derived
    PubMed: PMID 36522698 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  40. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial.
    Carson P, Teerlink JR, Komajda M, et al. · JACC Heart Fail · 2023 · Derived
    PubMed: PMID 36881400 · NCT03057977 · Heart Failure
  41. Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial.
    Butler J, Usman MS, Filippatos G, et al. · JAMA Cardiol · 2023 · Derived
    PubMed: PMID 37223933 · NCT03057951 · Heart Failure
  42. Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Bhm M, Anker S, Mahfoud F, et al. · Eur Heart J · 2023 · Derived
    PubMed: PMID 36478225 · NCT03057951 · Heart Failure
  43. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
    Barbour W, Wolff E, Puar P, et al. · BMC Cardiovasc Disord · 2023 · Derived
    PubMed: PMID 37964221 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  44. Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.
    Baekdal M, Nielsen SW, Hansen CP, et al. · Diabetes Care · 2023 · Derived
    PubMed: PMID 37703527 · NCT04061473 (Px-Meal) · Diabetes Mellitus
  45. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.
    Zhang L, Zhang Y, Shen S, et al. · Lancet Diabetes Endocrinol · 2023 · Background
    PubMed: PMID 37414069 · NCT07452913 · Diabetes Mellitus, Type 2
  46. Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors.
    Tuttle KR · J Clin Invest · 2023 · Background
    PubMed: PMID 36856116 · NCT07175051 (EMPA-CKD) · Albuminuria
  47. Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.
    Tsoukas MA, Woo V, Tobe SW, et al. · Diabetes Obes Metab · 2023 · Background
    PubMed: PMID 36942888 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  48. Dapagliflozin in people with chronic kidney disease.
    Sylvester RD, Khong TK · Drug Ther Bull · 2023 · Background
    PubMed: PMID 37257897 · NCT07175051 (EMPA-CKD) · Albuminuria
  49. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes.
    Schaub JA, AlAkwaa FM, McCown PJ, et al. · J Clin Invest · 2023 · Background
    PubMed: PMID 36637914 · NCT07175051 (EMPA-CKD) · Albuminuria
  50. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial.
    Ostadal P, Rokyta R, Karasek J, et al. · Circulation · 2023 · Background
    PubMed: PMID 36335478 · NCT06473844 · Inflammation
  51. Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study.
    Ng PY, Ng AK, Ip A, et al. · Crit Care Med · 2023 · Background
    PubMed: PMID 37026864 · NCT06473844 · Inflammation
  52. Early Clinical Experience with Dapagliflozin in Children with Heart Failure.
    Newland DM, Law YM, Albers EL, et al. · Pediatr Cardiol · 2023 · Background
    PubMed: PMID 35948644 · NCT06012266 · Heart Failure
  53. Time to revisit the true role of metformin in type 2 diabetes mellitus.
    Lopez-Candales A, Monte S, Sawalha K, et al. · Postgrad Med · 2023 · Background
    PubMed: PMID 37294638 · NCT07452913 · Diabetes Mellitus, Type 2
  54. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
    He Z, Lam K, Zhao W, et al. · Acta Diabetol · 2023 · Background
    PubMed: PMID 36576563 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  55. Sodium Transporters in Human Health and Disease.
    Gagnon KB, Delpire E · Front Physiol · 2023 · Background
    PubMed: PMID 33716756 · NCT06641128 · Arthritis, Rheumatoid
  56. A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation.
    Ahmed M, Saeed A, Khan MZ, et al. · Cureus · 2023 · Background
    PubMed: PMID 37809225 · NCT06759922 · Diabetes Mellitus, Type 2

2022 (100 papers)

  1. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis.
    Zou R, Shi W, Qiu J, et al. · Cardiovasc Diabetol · 2022 · Trial result
    PubMed: PMID 35705980 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  2. Empagliflozin in acute myocardial infarction: the EMMY trial.
    von Lewinski D, Kolesnik E, Tripolt NJ, et al. · Eur Heart J · 2022 · Trial result
    PubMed: PMID 36036746 · NCT03087773 (EMMY) · Heart Failure
  3. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells.
    Uthman L, Li X, Baartscheer A, et al. · Biomed Pharmacother · 2022 · Trial result
    PubMed: PMID 34896968 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  4. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  5. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  6. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Respir Med · 2022 · Trial result
    PubMed: PMID 34672950 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  7. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 35151397 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  8. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 35908569 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  9. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 34800427 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  10. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Heidenreich PA, Bozkurt B, Aguilar D, et al. · J Am Coll Cardiol · 2022 · Trial result
    PubMed: PMID 35379503 · NCT06706791
  11. Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
    Eliasson B, Ericsson Å, Fridhammar A, et al. · Pharmacoecon Open · 2022 · Trial result
    PubMed: PMID 35064550 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  12. Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
    Cheng H, Zhang Z, Zhang B, et al. · Diabetes Care · 2022 · Trial result
    PubMed: PMID 35263425 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
  13. Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
    Barış VÖ, Dinçsoy AB, Gedikli E, et al. · Cardiovasc Toxicol · 2022 · Trial result
    PubMed: PMID 34089496 · NCT06103279 · Neoplasms
  14. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
    Aroda VR, Bauer R, Christiansen E, et al. · Diabetes Obes Metab · 2022 · Trial result
    PubMed: PMID 35373893 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  15. Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin.
    Zeng YH, Liu SC, Lee CC, et al. · Sci Rep · 2022 · Derived
    PubMed: PMID 36224294 · NCT03458715
  16. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.
    Zannad F, Ferreira JP, Butler J, et al. · Eur Heart J · 2022 · Derived
    PubMed: PMID 36017745 · NCT03057977 · Heart Failure
  17. Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects.
    Zanchi A, Pruijm M, Muller ME, et al. · Front Cardiovasc Med · 2022 · Derived
    PubMed: PMID 35391843 · NCT03093103 (EMPA-REIN) · Kidney Diseases
  18. Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial.
    Wolsk E, Jürgens M, Schou M, et al. · Diabetes · 2022 · Derived
    PubMed: PMID 35061894 · NCT03151343 (SIMPLE)
  19. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
    Voors AA, Angermann CE, Teerlink JR, et al. · Nat Med · 2022 · Derived
    PubMed: PMID 35228754 · NCT04157751 · Heart Failure
  20. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
    Verma S, Dhingra NK, Butler J, et al. · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 34861154 · NCT03057977 · Heart Failure
  21. Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction.
    Vaduganathan M, Claggett BL, Inciardi RM, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35603667 · NCT03057951 · Heart Failure
  22. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
    Tuttle KR, Levin A, Nangaku M, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35472672 · NCT02589639 · Diabetes Mellitus, Type 2
  23. Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
    Thomsen RW, Christensen LWB, Kahlert J, et al. · Diabetes Ther · 2022 · Derived
    PubMed: PMID 36315384 · NCT03993132 · Diabetes Mellitus, Type 2
  24. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.
    Suijk DLS, van Baar MJB, van Bommel EJM, et al. · Clin J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 35322793 · NCT05210517 (UREX) · Diabetes Mellitus, Type 2
  25. Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial.
    Schietzel S, Bally L, Cereghetti G, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 35288397 · NCT04911660 (SWEETSTONE) · Kidney Calculi
  26. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
    Sargeant JA, King JA, Yates T, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35441435 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  27. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
    Sarak B, Verma S, David Mazer C, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34607574 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  28. Is the impact of add on heart failure therapy influenced by background therapy?
    Rydén L, Ferrannini G · Lancet Diabetes Endocrinol · 2022 · Derived
    PubMed: PMID 34861151 · NCT03057977 · Heart Failure
  29. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study.
    Prázný M, Suplotova L, Gumprecht J, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 36209118 · NCT03807440 · Diabetes Mellitus, Type 2
  30. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Posch MG, Walther N, Ferrannini E, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35817022 · NCT03462069 · Diabetes Mellitus
  31. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
    Pietschner R, Kolwelter J, Bosch A, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34753480 · NCT03128528 (ELSI)
  32. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C, Jung S, Korn M, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34481498 · NCT02752113 (ELMI) · Diabetes Mellitus, Type 2
  33. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
    Omar M, Jensen J, Kistorp C, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 35219331 · NCT03198585 (Empire HF)
  34. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
    Omar M, Jensen J, Burkhoff D, et al. · Circ Heart Fail · 2022 · Derived
    PubMed: PMID 34743533 · NCT03198585 (Empire HF)
  35. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M, Jensen J, Ali M, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 33404637 · NCT03198585 (Empire HF)
  36. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
    Nyström T, Toresson Grip E, Gunnarsson J, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 36097728 · NCT03817463 · Diabetes Mellitus, Type 2
  37. Can treatment response to SGLT2-inhibitors in syndrome of inappropriate antidiuresis be predicted by copeptin, natriuretic peptides and inflammatory markers?
    Nobbenhuis R, Refardt J, Vogt D, et al. · Biomarkers · 2022 · Derived
    PubMed: PMID 34412521 · NCT02874807 (SAND) · Hyponatremia
  38. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials.
    Mosenzon O, Capehorn MS, De Remigis A, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 36056351 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  39. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.
    Lytvyn Y, Kimura K, Peter N, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35862082 · NCT02632747 · Diabetes Mellitus, Type 2
  40. Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
    Liu SC, Lee CC, Chuang SM, et al. · Diabetes Metab · 2022 · Derived
    PubMed: PMID 32827752 · NCT03458715
  41. Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial.
    Kullmann S, Hummel J, Wagner R, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 34716213 · NCT03227484 · Prediabetic State
  42. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A, Prinz C, Fichtner F, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35695334 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  43. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
    Kosiborod MN, Angermann CE, Collins SP, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35377706 · NCT04157751 · Heart Failure
  44. Should knee extension strength testing be implemented as a screening test for identifying probable and confirmed sarcopenia in older T2DM patients?
    Kis O, Buch A, Eldor R, et al. · Eur Rev Aging Phys Act · 2022 · Derived
    PubMed: PMID 35086483 · NCT03560375 · Diabetes Mellitus, Type 2
  45. Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21.
    Kim ER, Kim SR, Cho W, et al. · Front Immunol · 2022 · Derived
    PubMed: PMID 35572519 · NCT02964572
  46. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
    Jünger C, Prochaska JH, Gori T, et al. · J Cardiovasc Med (Hagerstown) · 2022 · Derived
    PubMed: PMID 34939776 · NCT02932436 (EmDia) · Diabetes Mellitus, Type 2
  47. Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial.
    Jensen J, Omar M, Kistorp C, et al. · Circ Heart Fail · 2022 · Derived
    PubMed: PMID 35973031 · NCT03198585 (Empire HF)
  48. Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
    Januzzi JL, Butler J, Zannad F, et al. · JACC Heart Fail · 2022 · Derived
    PubMed: PMID 35670067 · NCT03057951 · Heart Failure
  49. Eight weeks of empagliflozin does not affect pancreatic fat content and insulin secretion in people with prediabetes.
    Hummel J, Machann J, Dannecker C, et al. · Diabetes Obes Metab · 2022 · Derived
    PubMed: PMID 35475570 · NCT03227484 · Prediabetic State
  50. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C, Park YS, Piechotta V, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35713300 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  51. Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate.
    Harmacek D, Pruijm M, Burnier M, et al. · J Am Soc Nephrol · 2022 · Derived
    PubMed: PMID 35387874 · NCT03093103 (EMPA-REIN) · Kidney Diseases
  52. Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.
    Gessner A, Gemeinhardt A, Bosch A, et al. · Cardiovasc Diabetol · 2022 · Derived
    PubMed: PMID 34991562 · NCT02471963 · Diabetes Mellitus, Type 2
  53. Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes.
    Garcia-Tirado J, Farhy L, Nass R, et al. · Diabetes Technol Ther · 2022 · Derived
    PubMed: PMID 35255229 · NCT04201496 (CiQ-SGLT2) · Diabetes Mellitus, Type 1
  54. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Filippatos G, Butler J, Farmakis D, et al. · Circulation · 2022 · Derived
    PubMed: PMID 35762322 · NCT03057951 · Heart Failure
  55. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP, Zannad F, Butler J, et al. · JAMA Cardiol · 2022 · Derived
    PubMed: PMID 36129693 · NCT03057977 · Heart Failure
  56. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Ferreira JP, Zannad F, Butler J, et al. · Eur Heart J · 2022 · Derived
    PubMed: PMID 35687107 · NCT03057951 · Heart Failure
  57. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Ferreira JP, Butler J, Zannad F, et al. · J Am Coll Cardiol · 2022 · Derived
    PubMed: PMID 35331406 · NCT03057951 · Heart Failure
  58. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.
    Ferreira JP, Anker SD, Butler J, et al. · Eur J Heart Fail · 2022 · Derived
    PubMed: PMID 34957660 · NCT03057977 · Heart Failure
  59. Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass.
    Ferreira A, Emara AFA, Herzig D, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 36123073 · NCT05057819 · Hypoglycemia
  60. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J, Filippatos G, Siddiqi TJ, et al. · Circulation · 2022 · Derived
    PubMed: PMID 36098051 · NCT03057951 · Heart Failure
  61. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J, Filippatos G, Jamal Siddiqi T, et al. · Circulation · 2022 · Derived
    PubMed: PMID 34779658 · NCT03057951 · Heart Failure
  62. Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial.
    Aamir AH, Raja UY, Qureshi FM, et al. · BMC Endocr Disord · 2022 · Derived
    PubMed: PMID 36443769 · NCT04665284 (SAFE-PAK) · Diabetes Mellitus, Type 2
  63. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhang Y, Liu X, Zhang H, et al. · Front Endocrinol (Lausanne) · 2022 · Background
    PubMed: PMID 35282455 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  64. Role of NLRP3 Inflammasome in Rheumatoid Arthritis.
    Yin H, Liu N, Sigdel KR, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 35833125 · NCT06641128 · Arthritis, Rheumatoid
  65. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
    Wu MZ, Chandramouli C, Wong PF, et al. · Diabetes Metab · 2022 · Background
    PubMed: PMID 35753654 · NCT06473844 · Inflammation
  66. The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
    Wilding JPH, Evans M, Fernando K, et al. · Diabetes Ther · 2022 · Background
    PubMed: PMID 35307801 · NCT07452913 · Diabetes Mellitus, Type 2
  67. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Vaduganathan M, Claggett BL, Jhund P, et al. · JAMA Cardiol · 2022 · Background
    PubMed: PMID 36190011 · NCT06473844 · Inflammation
  68. The burden and risks of emerging complications of diabetes mellitus.
    Tomic D, Shaw JE, Magliano DJ, et al. · Nat Rev Endocrinol · 2022 · Background
    PubMed: PMID 35668219 · NCT06759922 · Diabetes Mellitus, Type 2
  69. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis.
    Tian Q, Guo K, Deng J, et al. · J Cell Mol Med · 2022 · Background
    PubMed: PMID 34878225 · NCT07175051 (EMPA-CKD) · Albuminuria
  70. The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents.
    Theofilis P, Sagris M, Oikonomou E, et al. · Int Immunopharmacol · 2022 · Background
    PubMed: PMID 35908505 · NCT06473844 · Inflammation
  71. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes.
    Theofilis P, Sagris M, Oikonomou E, et al. · Diabetes Res Clin Pract · 2022 · Background
    PubMed: PMID 35577035 · NCT06641128 · Arthritis, Rheumatoid
  72. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    Solomon SD, McMurray JJV, Claggett B, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 36027570 · NCT06473844 · Inflammation
  73. Improvement of hemolytic anemia with GBT1118 is renoprotective in transgenic sickle mice.
    Ren G, Setty S, Zhang X, et al. · Blood Adv · 2022 · Background
    PubMed: PMID 35759756 · NCT07175051 (EMPA-CKD) · Albuminuria
  74. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V, De Laurentiis M, Rea D, et al. · Cardiovasc Diabetol · 2022 · Background
    PubMed: PMID 34301253 · NCT06641128 · Arthritis, Rheumatoid
  75. Non-alcoholic fatty liver disease.
    Powell EE, Wong VW, Rinella M, et al. · Lancet · 2022 · Background
    PubMed: PMID 33894145 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  76. Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial.
    Pasqua MR, Jafar A, Kobayati A, et al. · Diabetes Care · 2022 · Background
    PubMed: PMID 36331522 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  77. Contrast-induced acute kidney injury: A review of practical points.
    Ozkok S, Ozkok A · World J Nephrol · 2022 · Background
    PubMed: PMID 28540198 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  78. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium · Lancet · 2022 · Background
    PubMed: PMID 36351458 · NCT06473844 · Inflammation
  79. The Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study.
    Mieno H, Yoneda K, Yamazaki M, et al. · BMJ Open Ophthalmol · 2022 · Background
    PubMed: PMID 30123844 · NCT04215445 · Diabetes Mellitus
  80. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease.
    Liu JJ, Ghosh S, Kovalik JP, et al. · Kidney Int Rep · 2022 · Background
    PubMed: PMID 29142974 · NCT03933956 ((MEDiaN)) · Diabetic Nephropathies
  81. Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19.
    Ling L, Chen Z, Lui G, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 34938289 · NCT06473844 · Inflammation
  82. Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Gillis KA, Brooksbank KJM, et al. · Circulation · 2022 · Background
    PubMed: PMID 35877829 · NCT07175051 (EMPA-CKD) · Albuminuria
  83. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.
    Lamontagne F, Masse MH, Menard J, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35704292 · NCT06473844 · Inflammation
  84. Association between reduced quality of life and depression in patients with type 2 diabetes mellitus: a cohort study in a Mexican population.
    Juárez-Rojop IE, Fortuny-Falconi CM, González-Castro TB, et al. · Neuropsychiatr Dis Treat · 2022 · Background
    PubMed: PMID 30323600 · NCT04131582 (4T) · Insulin Resistance
  85. Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Janani L, Bamehr H, Tanha K, et al. · Drug Res (Stuttg) · 2022 · Background
    PubMed: PMID 34388848 · NCT06759922 · Diabetes Mellitus, Type 2
  86. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
    Huang J, Liu X, Wei Y, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 35309368 · NCT06759922 · Diabetes Mellitus, Type 2
  87. Potential Hypoxic Renal Injury in Patients With Diabetes on SGLT2 Inhibitors: Caution Regarding Concomitant Use of NSAIDs and Iodinated Contrast Media.
    Heyman SN, Khamaisi M, Rosen S, et al. · Diabetes Care · 2022 · Background
    PubMed: PMID 28130255 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  88. Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway.
    Heo YJ, Lee N, Choi SE, et al. · Biomedicines · 2022 · Background
    PubMed: PMID 35625768 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  89. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China.
    He K, Hu Y, Shi JC, et al. · Ther Clin Risk Manag · 2022 · Background
    PubMed: PMID 29520146 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  90. Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial.
    Haidar A, Lovblom LE, Cardinez N, et al. · Nat Med · 2022 · Background
    PubMed: PMID 35551290 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  91. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.
    Guo Q, Wang Y, Xu D, et al. · Bone Res · 2022 · Background
    PubMed: PMID 29736302 · NCT06641128 · Arthritis, Rheumatoid
  92. Parafoveal OCT Angiography Features in Diabetic Patients without Clinical Diabetic Retinopathy: A Qualitative and Quantitative Analysis.
    Goudot MM, Sikorav A, Semoun O, et al. · J Ophthalmol · 2022 · Background
    PubMed: PMID 28761762 · NCT04215445 · Diabetes Mellitus
  93. Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial.
    Ersbøll M, Jürgens M, Hasbak P, et al. · Int J Cardiovasc Imaging · 2022 · Background
    PubMed: PMID 34669059 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  94. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
    ElSayed NA, Aleppo G, Aroda VR, et al. · Diabetes Care · 2022 · Background
    PubMed: PMID 36507650 · NCT06759922 · Diabetes Mellitus, Type 2
  95. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ, Aroda VR, Collins BS, et al. · Diabetologia · 2022 · Background
    PubMed: PMID 36151309 · NCT06759922 · Diabetes Mellitus, Type 2
  96. Gliflozins in the Management of Cardiovascular Disease.
    Braunwald E · N Engl J Med · 2022 · Background
    PubMed: PMID 35613023 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  97. Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.
    Bourke J, Turner C, Bradlow W, et al. · Open Heart · 2022 · Background
    PubMed: PMID 36252992 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  98. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.
    Authors/Task Force Members:, McDonagh TA, Metra M, et al. · Eur J Heart Fail · 2022 · Background
    PubMed: PMID 35083827 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  99. Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis.
    Ataga KI, Zhou Q, Saraf SL, et al. · Blood Adv · 2022 · Background
    PubMed: PMID 35696734 · NCT07175051 (EMPA-CKD) · Albuminuria
  100. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
    Androutsakos T, Nasiri-Ansari N, Bakasis AD, et al. · Int J Mol Sci · 2022 · Background
    PubMed: PMID 35328527 · NCT05605158 · Non-alcoholic Fatty Liver Disease

2021 (95 papers)

  1. Sodium-Glucose Co-Transporter 2 Inhibition With Empagliflozin Improves Cardiac Function After Cardiac Arrest in Rats by Enhancing Mitochondrial Energy Metabolism.
    Tan Y, Yu K, Liang L, et al. · Front Pharmacol · 2021 · Trial result
    PubMed: PMID 34712142 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  2. Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department.
    Stubblefield WB, Jenkins CA, Liu D, et al. · Circ Cardiovasc Qual Outcomes · 2021 · Trial result
    PubMed: PMID 34555929 · NCT06706791
  3. Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels.
    Seo MS, Jung HS, An JR, et al. · Toxicol Appl Pharmacol · 2021 · Trial result
    PubMed: PMID 32717242 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  4. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. · J Am Coll Cardiol · 2021 · Trial result
    PubMed: PMID 33197559 · NCT03485222 (EMPA-TROPISM) · Heart Failure
  5. Dexamethasone in Hospitalized Patients with Covid-19.
    RECOVERY Collaborative Group, Horby P, Lim WS, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 32678530 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  6. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2021 · Trial result
    PubMed: PMID 33031764 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  7. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2021 · Trial result
    PubMed: PMID 33545096 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  8. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME, Qintar M, Windsor SL, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 33550815 · NCT03030222 (EMBRACE-HF) · Heart Failure
  9. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
    McDonagh TA, Metra M, Adamo M, et al. · Eur Heart J · 2021 · Trial result
    PubMed: PMID 34649282 · NCT06103279 · Neoplasms
  10. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 33186500 · NCT05580510 · Heart Failure
  11. Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.
    Kuchay MS, Mishra SK, Mehta Y, et al. · Diabetes Metab Syndr · 2021 · Trial result
    PubMed: PMID 33915345 · NCT06187285 · Diabetes Mellitus, Type 2
  12. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D, Pabel S, Tian Y, et al. · Cardiovasc Res · 2021 · Trial result
    PubMed: PMID 32396609 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  13. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations.
    Klen J, Dolžan V · Int J Mol Sci · 2021 · Trial result
    PubMed: PMID 34575958 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  14. Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.
    Jhund PS, Ponikowski P, Docherty KF, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 33832352 · NCT05580510 · Heart Failure
  15. Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies.
    Eliaa SG, Al-Karmalawy AA, Saleh RM, et al. · ACS Pharmacol Transl Sci · 2021 · Trial result
    PubMed: PMID 33344906 · NCT06103279 · Neoplasms
  16. Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients.
    Chang WT, Lin YW, Ho CH, et al. · Arch Toxicol · 2021 · Trial result
    PubMed: PMID 33211168 · NCT06103279 · Neoplasms
  17. Heart failure drug treatment: the fantastic four.
    Bauersachs J · Eur Heart J · 2021 · Trial result
    PubMed: PMID 33447845 · NCT05580510 · Heart Failure
  18. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F, Ferreira JP, Pocock SJ, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33095032 · NCT03057977 · Heart Failure
  19. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
    Zanchi A, Burnier M, Muller ME, et al. · J Am Heart Assoc · 2021 · Derived
    PubMed: PMID 32567439 · NCT03093103 (EMPA-REIN) · Kidney Diseases
  20. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
    Yabe D, Shiki K, Suzaki K, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33827843 · NCT04531462 · Diabetes Mellitus, Type 2
  21. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives.
    Tume LN, Menzies JC, Ray S, et al. · Pediatr Crit Care Med · 2021 · Derived
    PubMed: PMID 33394942 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  22. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Thethi TK, Pratley R, Meier JJ, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 32267058 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  23. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
    Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 34325888 · NCT03485222 (EMPA-TROPISM) · Heart Failure
  24. Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
    Pocock SJ, Ferreira JP, Gregson J, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 34423361 · NCT03057977 · Heart Failure
  25. SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.
    Piperidou A, Loutradis C, Sarafidis P, et al. · J Hum Hypertens · 2021 · Derived
    PubMed: PMID 32778748 · NCT03594110 · Renal Insufficiency, Chronic
  26. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V, Iannizzi C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34013969 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  27. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
    Packer M, Butler J, Zannad F, et al. · Circulation · 2021 · Derived
    PubMed: PMID 34459213 · NCT03057977 · Heart Failure
  28. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 33736819 · NCT03057977 · Heart Failure
  29. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M, Anker SD, Butler J, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33081531 · NCT03057977 · Heart Failure
  30. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure.
    Omar M, Jensen J, Frederiksen PH, et al. · JACC Heart Fail · 2021 · Derived
    PubMed: PMID 34509409 · NCT03198585 (Empire HF)
  31. Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure.
    Nassif ME, Spertus JA, Tang F, et al. · Circ Heart Fail · 2021 · Derived
    PubMed: PMID 34696602 · NCT03030222 (EMBRACE-HF) · Heart Failure
  32. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA, Mordi IR, Singh JS, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32865004 · NCT03226457 (RECEDE-CHF) · Diabetes Mellitus, Type 2
  33. Colchicine for the treatment of COVID-19.
    Mikolajewska A, Fischer AL, Piechotta V, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34658014 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  34. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
    Mason T, Coelho-Filho OR, Verma S, et al. · JACC Cardiovasc Imaging · 2021 · Derived
    PubMed: PMID 33454272 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  35. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I, Capehorn MS, Catarig AM, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 32827435 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  36. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Lam CSP, Ferreira JP, Pfarr E, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 34184057 · NCT03057977 · Heart Failure
  37. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, et al. · Diabetes Res Clin Pract · 2021 · Derived
    PubMed: PMID 34740742 · NCT03748810
  38. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34473343 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  39. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
    Kim YK, Hwang JG, Park MK, et al. · Drug Des Devel Ther · 2021 · Derived
    PubMed: PMID 33953542 · NCT02854748 · Diabetes Mellitus, Type 2
  40. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T, Mizuno A, Takaoka Y, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34693515 · NCT03057951 · Heart Failure
  41. Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
    Jung S, Bosch A, Kannenkeril D, et al. · Eur Heart J Cardiovasc Pharmacother · 2021 · Derived
    PubMed: PMID 31816038 · NCT02752113 (ELMI) · Diabetes Mellitus, Type 2
  42. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
    Jensen J, Omar M, Kistorp C, et al. · Lancet Diabetes Endocrinol · 2021 · Derived
    PubMed: PMID 33357505 · NCT03198585 (Empire HF)
  43. Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
    Jensen J, Omar M, Kistorp C, et al. · Circulation · 2021 · Derived
    PubMed: PMID 34061581 · NCT03198585 (Empire HF)
  44. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
    Januzzi JL, Zannad F, Anker SD, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 34556318 · NCT03057977 · Heart Failure
  45. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Husain M, Bain SC, Jeppesen OK, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 31903692 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  46. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
    Hundertmark MJ, Agbaje OF, Coleman R, et al. · ESC Heart Fail · 2021 · Derived
    PubMed: PMID 33960149 · NCT03332212 · Heart Failure
  47. Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β.
    Hepprich M, Wiedemann SJ, Schelker BL, et al. · Cell Metab · 2021 · Derived
    PubMed: PMID 32197070 · NCT03200782 (Hypo-BEAR) · Hypoglycemia
  48. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
    Hædersdal S, Lund A, Nielsen-Hannerup E, et al. · Diabetes · 2021 · Derived
    PubMed: PMID 33004472 · NCT02792400 · Diabetes Mellitus, Type 2
  49. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
    Griffin M, Rao VS, Ivey-Miranda J, et al. · Circulation · 2021 · Derived
    PubMed: PMID 32410463 · NCT03027960 (EMPA) · Diabetes Mellitus, Type 2
  50. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B, Ancel P, Abdullah AE, et al. · Cardiovasc Diabetol · 2021 · Derived
    PubMed: PMID 33648515 · NCT03118336 (EMPACEF) · Diabetes Mellitus, Type 2
  51. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
    Franklin JM, Patorno E, Desai RJ, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33327727 · NCT04215536 · Diabetes Mellitus
  52. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
    Ferreira JP, Zannad F, Pocock SJ, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 33736821 · NCT03057977 · Heart Failure
  53. The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial.
    ElDash RM, Raslan MA, Shaheen SM, et al. · F1000Res · 2021 · Derived
    PubMed: PMID 34123370 · NCT03895229 · Diabetes Mellitus
  54. STAT1 Dissociates Adipose Tissue Inflammation From Insulin Sensitivity in Obesity.
    Cox AR, Chernis N, Bader DA, et al. · Diabetes · 2021 · Derived
    PubMed: PMID 32994273 · NCT02792400 · Diabetes Mellitus, Type 2
  55. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
    Butler J, Anker SD, Filippatos G, et al. · Eur Heart J · 2021 · Derived
    PubMed: PMID 33420498 · NCT03057977 · Heart Failure
  56. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
    Böhm M, Anker SD, Butler J, et al. · J Am Coll Cardiol · 2021 · Derived
    PubMed: PMID 34556320 · NCT03057977 · Heart Failure
  57. Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Anker SD, Ponikowski P, Wanner C, et al. · Circulation · 2021 · Derived
    PubMed: PMID 34397263 · NCT03448419 · Heart Failure
  58. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD, Butler J, Filippatos G, et al. · Circulation · 2021 · Derived
    PubMed: PMID 33175585 · NCT03057977 · Heart Failure
  59. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD, Butler J, Filippatos G, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34449189 · NCT03057951 · Heart Failure
  60. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
    Almaimani M, Sridhar VS, Cherney DZI, et al. · Curr Opin Nephrol Hypertens · 2021 · Derived
    PubMed: PMID 34074889 · NCT03594110 · Renal Insufficiency, Chronic
  61. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt.
    Tomah S, Hamdy O, Abuelmagd MM, et al. · BMJ Open Gastroenterol · 2021 · Background
    PubMed: PMID 34610926 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  62. Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD.
    Srivastava A, Cai X, Lee J, et al. · Clin J Am Soc Nephrol · 2021 · Background
    PubMed: PMID 32345747 · NCT07175051 (EMPA-CKD) · Albuminuria
  63. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Soga F, Tanaka H, Tatsumi K, et al. · Intern Med · 2021 · Background
    PubMed: PMID 34334588 · NCT06249945 (EMPA-PRED) · Heart Failure
  64. Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA.
    Shin H, Schneeweiss S, Glynn RJ, et al. · Diabetes Care · 2021 · Background
    PubMed: PMID 34385345 · NCT06759922 · Diabetes Mellitus, Type 2
  65. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W, Kubota Y, Hoshika Y, et al. · Cardiovasc Diabetol · 2021 · Background
    PubMed: PMID 32977831 · NCT06313008 · Diabetes Mellitus, Type 2
  66. Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.
    Shim CY, Seo J, Cho I, et al. · Circulation · 2021 · Background
    PubMed: PMID 33186508 · NCT06249945 (EMPA-PRED) · Heart Failure
  67. Heart failure management in dialysis patients: Many treatment options with no clear evidence.
    Roehm B, Gulati G, Weiner DE, et al. · Semin Dial · 2021 · Background
    PubMed: PMID 32282987 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  68. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M, Thiele K, Hartmann NK, et al. · Cardiovasc Diabetol · 2021 · Background
    PubMed: PMID 33413355 · NCT06249945 (EMPA-PRED) · Heart Failure
  69. Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.
    Niss O, Lane A, Asnani MR, et al. · Blood Adv · 2021 · Background
    PubMed: PMID 32289161 · NCT07175051 (EMPA-CKD) · Albuminuria
  70. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    McDonagh TA, Metra M, Adamo M, et al. · Eur Heart J · 2021 · Background
    PubMed: PMID 34447992 · NCT06706791
  71. Recent and Upcoming Drug Therapies for Pediatric Heart Failure.
    Loss KL, Shaddy RE, Kantor PF, et al. · Front Pediatr · 2021 · Background
    PubMed: PMID 34858897 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  72. Characteristics and outcomes of patients admitted to adult intensive care units in Hong Kong: a population retrospective cohort study from 2008 to 2018.
    Ling L, Ho CM, Ng PY, et al. · J Intensive Care · 2021 · Background
    PubMed: PMID 33407925 · NCT06473844 · Inflammation
  73. The Prevalence of Diabetic Microvascular Complications in China and the USA.
    Lin YK, Gao B, Liu L, et al. · Curr Diab Rep · 2021 · Background
    PubMed: PMID 33835284 · NCT05359432 · Diabetes Mellitus, Type 2
  74. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis.
    Lian J, Fu J · Front Endocrinol (Lausanne) · 2021 · Background
    PubMed: PMID 33995271 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  75. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X, Lu Q, Qiu Y, et al. · J Am Heart Assoc · 2021 · Background
    PubMed: PMID 33719499 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  76. Major signaling pathways and key mediators of macrophages in acute kidney injury (Review).
    Li N, Chen J, Wang P, et al. · Mol Med Rep · 2021 · Background
    PubMed: PMID 33880578 · NCT06473844 · Inflammation
  77. Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways.
    Lee N, Heo YJ, Choi SE, et al. · J Immunol Res · 2021 · Background
    PubMed: PMID 34124273 · NCT06473844 · Inflammation
  78. High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia.
    Lebensburger JD, Gossett J, Zahr R, et al. · Haematologica · 2021 · Background
    PubMed: PMID 32107332 · NCT07175051 (EMPA-CKD) · Albuminuria
  79. The prognostic importance of subclinical heart failure in stable coronary heart disease patients.
    König P, Mayer O, Bruthans J, et al. · Acta Cardiol · 2021 · Background
    PubMed: PMID 30942129 · NCT05911724 · Heart Failure
  80. Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors.
    Kogot-Levin A, Hinden L, Riahi Y, et al. · Cell Rep · 2021 · Background
    PubMed: PMID 32726619 · NCT07175051 (EMPA-CKD) · Albuminuria
  81. Chronic kidney disease.
    Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. · Lancet · 2021 · Background
    PubMed: PMID 34175022 · NCT06249945 (EMPA-PRED) · Heart Failure
  82. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N, Greene T, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021 · Background
    PubMed: PMID 34619106 · NCT07175051 (EMPA-CKD) · Albuminuria
  83. 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.
    Hur KY, Moon MK, Park JS, et al. · Diabetes Metab J · 2021 · Background
    PubMed: PMID 34352984 · NCT06759922 · Diabetes Mellitus, Type 2
  84. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    Hu J, Wu Y, Zhou X, et al. · J Cardiovasc Pharmacol · 2021 · Background
    PubMed: PMID 33030857 · NCT05580510 · Heart Failure
  85. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL, Jongs N, Chertow GM, et al. · Lancet Diabetes Endocrinol · 2021 · Background
    PubMed: PMID 34619108 · NCT07175051 (EMPA-CKD) · Albuminuria
  86. Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial.
    Haidar A, Yale JF, Lovblom LE, et al. · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 33528904 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  87. The mTOR-Autophagy Axis and the Control of Metabolism.
    Deleyto-Seldas N, Efeyan A · Front Cell Dev Biol · 2021 · Background
    PubMed: PMID 34277603 · NCT07175051 (EMPA-CKD) · Albuminuria
  88. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
    Dejgaard TF, Schmidt S, Frandsen CS, et al. · Diabetes Obes Metab · 2021 · Background
    PubMed: PMID 31696598 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  89. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
    Cohen JB, Schrauben SJ, Zhao L, et al. · JACC Heart Fail · 2021 · Background
    PubMed: PMID 31926856 · NCT06249945 (EMPA-PRED) · Heart Failure
  90. End-systolic wall stress in aortic stenosis: comparing symptomatic and asymptomatic patients.
    Carter-Storch R, Moller JE, Christensen NL, et al. · Open Heart · 2021 · Background
    PubMed: PMID 31168387 · NCT05084235 · Heart Failure
  91. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
    Capehorn MS, Catarig AM, Furberg JK, et al. · Diabetes Metab · 2021 · Background
    PubMed: PMID 31539622 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  92. Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis.
    Ataga KI, Zhou Q, Derebail VK, et al. · Haematologica · 2021 · Background
    PubMed: PMID 33179474 · NCT07175051 (EMPA-CKD) · Albuminuria
  93. Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors.
    Arnaert S, De Meester P, Troost E, et al. · ESC Heart Fail · 2021 · Background
    PubMed: PMID 33960724 · NCT05580510 · Heart Failure
  94. Heart failure from heart muscle disease in childhood: a 5-10 year follow-up study in the UK and Ireland.
    Andrews RE, Fenton MJ, Dominguez T, et al. · ESC Heart Fail · 2021 · Background
    PubMed: PMID 27812385 · NCT06012266 · Heart Failure
  95. Medical management of pediatric heart failure.
    Ahmed H, VanderPluym C · Cardiovasc Diagn Ther · 2021 · Background
    PubMed: PMID 33708503 · NCT06012266 · Heart Failure

2020 (79 papers)

  1. Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
    Zhang Z, Zhang B, Wang X, et al. · Diabetes Care · 2020 · Trial result
    PubMed: PMID 31221697 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
  2. TLR9 Binding to Beclin 1 and Mitochondrial SIRT3 by a Sodium-Glucose Co-Transporter 2 Inhibitor Protects the Heart from Doxorubicin Toxicity.
    Wang CY, Chen CC, Lin MH, et al. · Biology (Basel) · 2020 · Trial result
    PubMed: PMID 33138323 · NCT06103279 · Neoplasms
  3. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats.
    Shao Q, Meng L, Lee S, et al. · Cardiovasc Diabetol · 2020 · Trial result
    PubMed: PMID 31779619 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  4. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ · Nat Rev Endocrinol · 2020 · Trial result
    PubMed: PMID 32855502 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  5. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation.
    Sayour AA, Korkmaz-Icöz S, Loganathan S, et al. · J Transl Med · 2020 · Trial result
    PubMed: PMID 30992077 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  6. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
    Sabatino J, De Rosa S, Tammè L, et al. · Cardiovasc Diabetol · 2020 · Trial result
    PubMed: PMID 32414364 · NCT06103279 · Neoplasms
  7. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW, Rosenstock J, Canani LH, et al. · Diabetes Care · 2020 · Trial result
    PubMed: PMID 31530666 · NCT02863328 (PIONEER 2) · Diabetes Mellitus, Type 2
  8. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
    RECOVERY Collaborative Group, Horby P, Mafham M, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 33031652 · NCT04381936 (RECOVERY) · Community-Acquired Pneumonia
  9. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    Packer M, Anker SD, Butler J, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32865377 · NCT06706791
  10. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.
    Oh CM, Cho S, Jang JY, et al. · Korean Circ J · 2020 · Trial result
    PubMed: PMID 31456369 · NCT06103279 · Neoplasms
  11. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    Nougué H, Pezel T, Picard F, et al. · Eur J Heart Fail · 2020 · Trial result
    PubMed: PMID 30520545 · NCT05580510 · Heart Failure
  12. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway.
    Lu Q, Liu J, Li X, et al. · Mol Cell Endocrinol · 2020 · Trial result
    PubMed: PMID 31759100 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  13. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury.
    Lahnwong C, Palee S, Apaijai N, et al. · Cardiovasc Diabetol · 2020 · Trial result
    PubMed: PMID 32539724 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  14. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
    Javed Z, Papageorgiou M, Deshmukh H, et al. · Clin Endocrinol (Oxf) · 2020 · Trial result
    PubMed: PMID 30866088 · NCT03008551 · Polycystic Ovary Syndrome
  15. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
    Halden TAS, Kvitne KE, Midtvedt K, et al. · Diabetes Care · 2020 · Trial result
    PubMed: PMID 30862658 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  16. Linagliptin plus insulin for hyperglycemia immediately after renal transplantation: A comparative study.
    Guardado-Mendoza R, Cázares-Sánchez D, Evia-Viscarra ML, et al. · Diabetes Res Clin Pract · 2020 · Trial result
    PubMed: PMID 31539565 · NCT06098625 (EmLina Renal) · Diabetes Mellitus
  17. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.
    Connelly KA, Zhang Y, Visram A, et al. · JACC Basic Transl Sci · 2020 · Trial result
    PubMed: PMID 30847416 · NCT06103279 · Neoplasms
  18. Bile Acids as Metabolic Regulators and Nutrient Sensors.
    Chiang JYL, Ferrell JM · Annu Rev Nutr · 2020 · Trial result
    PubMed: PMID 31018107 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  19. The Multi-Functional Calcium/Calmodulin Stimulated Protein Kinase (CaMK) Family: Emerging Targets for Anti-Cancer Therapeutic Intervention.
    Brzozowski JS, Skelding KA · Pharmaceuticals (Basel) · 2020 · Trial result
    PubMed: PMID 30621060 · NCT06103279 · Neoplasms
  20. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S, Mazer CD, Yan AT, et al. · Circulation · 2020 · Derived
    PubMed: PMID 31434508 · NCT02998970 (EMPA-HEART) · Diabetes Mellitus, Type 2
  21. Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.
    Terauchi Y, Utsunomiya K, Yasui A, et al. · Diabetes Ther · 2020 · Derived
    PubMed: PMID 30912033 · NCT02589626 · Diabetes Mellitus, Type 2
  22. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.
    Schwaiger E, Burghart L, Signorini L, et al. · Am J Transplant · 2020 · Derived
    PubMed: PMID 30585690 · NCT03113110 (EMPTRA-DM)
  23. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E, Pawar A, Franklin JM, et al. · Circulation · 2020 · Derived
    PubMed: PMID 30955357 · NCT03363464 · Diabetes Mellitus, Type 2
  24. Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Nishimura R, Tanaka Y, Koiwai K, et al. · Adv Ther · 2020 · Derived
    PubMed: PMID 31444706 · NCT01947855 · Diabetes Mellitus, Type 2
  25. Effects of Empagliflozin Treatment on Glycerol-Derived Hepatic Gluconeogenesis in Adults with Obesity: A Randomized Clinical Trial.
    Neeland IJ, de Albuquerque Rocha N, Hughes C, et al. · Obesity (Silver Spring) · 2020 · Derived
    PubMed: PMID 32568464 · NCT02833415 · Diabetes Mellitus
  26. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 31081589 · NCT03448419 · Heart Failure
  27. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Toyama T, Oshima M, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32803882 · NCT03642184 · Diabetes Mellitus
  28. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL, Vethakkan SR, Nik Mustapha NR, et al. · Dig Dis Sci · 2020 · Derived
    PubMed: PMID 30684076 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  29. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
    Jürgens M, Schou M, Hasbak P, et al. · BMJ Open · 2020 · Derived
    PubMed: PMID 31780586 · NCT03151343 (SIMPLE)
  30. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J, Omar M, Kistorp C, et al. · Trials · 2020 · Derived
    PubMed: PMID 31227014 · NCT03198585 (Empire HF)
  31. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE, Foresto RD, Ribeiro AB, et al. · Rev Assoc Med Bras (1992) · 2020 · Derived
    PubMed: PMID 31939531 · NCT03594110 · Renal Insufficiency, Chronic
  32. Metformin monotherapy for adults with type 2 diabetes mellitus.
    Gnesin F, Thuesen ACB, Kähler LKA, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32501595 · NCT01001962 (PREHYPD) · Diabetes Mellitus, Type 2
  33. Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
    Ferdinand KC, Izzo JL, Lee J, et al. · Circulation · 2020 · Derived
    PubMed: PMID 30786754 · NCT02182830 · Diabetes Mellitus, Type 2
  34. The NEW-HOPE study and emerging therapies for difficult-to-control and resistant hypertension.
    Ferdinand KC, Harrison D, Johnson A, et al. · Prog Cardiovasc Dis · 2020 · Derived
    PubMed: PMID 31923435 · NCT02182830 · Diabetes Mellitus, Type 2
  35. The effect of circuit resistance training, empagliflozin or "vegeterranean diet" on physical and metabolic function in older subjects with type 2 diabetes: a study protocol for a randomized control trial (CEV-65 trial).
    Buch A, Eldor R, Kis O, et al. · BMC Geriatr · 2020 · Derived
    PubMed: PMID 31438863 · NCT03560375 · Diabetes Mellitus, Type 2
  36. Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
    Bjornstad P, Laffel L, Tamborlane WV, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 29941496 · NCT02121483 · Diabetes Mellitus, Type 2
  37. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT, Ponikowski P, Brueckmann M, et al. · Eur J Heart Fail · 2020 · Derived
    PubMed: PMID 31218819 · NCT03448419 · Heart Failure
  38. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B, Bhosekar V, Busch R, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 30833170 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  39. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
    Zelniker TA, Braunwald E · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 32000955 · NCT06012266 · Heart Failure
  40. Kidney biopsy findings in children with sickle cell disease: a Midwest Pediatric Nephrology Consortium study.
    Zahr RS, Yee ME, Weaver J, et al. · Pediatr Nephrol · 2020 · Background
    PubMed: PMID 30945006 · NCT07175051 (EMPA-CKD) · Albuminuria
  41. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.
    Yu H, Woo VC · Diabetes Metab Syndr Obes · 2020 · Background
    PubMed: PMID 28769579 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  42. Combination of Functional Magnetic Resonance Imaging and Histopathologic Analysis to Evaluate Interstitial Fibrosis in Kidney Allografts.
    Wang W, Yu Y, Wen J, et al. · Clin J Am Soc Nephrol · 2020 · Background
    PubMed: PMID 31416890 · NCT07175051 (EMPA-CKD) · Albuminuria
  43. Evolving Nutritional Therapy for Diabetes Mellitus.
    Uusitupa M, Schwab U · Nutrients · 2020 · Background
    PubMed: PMID 32041141 · NCT06759922 · Diabetes Mellitus, Type 2
  44. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Tripolt NJ, Kolesnik E, Pferschy PN, et al. · Am Heart J · 2020 · Background
    PubMed: PMID 31901799 · NCT03087773 (EMMY) · Heart Failure
  45. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Tasar O, Karabay AK, Oduncu V, et al. · Coron Artery Dis · 2020 · Background
    PubMed: PMID 31026233 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  46. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N, Häring HU, Cusi K, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 30174213 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  47. Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?
    Shah KS, Fang JC · Curr Hypertens Rep · 2020 · Background
    PubMed: PMID 31599363 · NCT06249945 (EMPA-PRED) · Heart Failure
  48. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 30999996 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  49. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
    Saeedi P, Petersohn I, Salpea P, et al. · Diabetes Res Clin Pract · 2020 · Background
    PubMed: PMID 31518657 · NCT05359432 · Diabetes Mellitus, Type 2
  50. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.
    Rudd KE, Johnson SC, Agesa KM, et al. · Lancet · 2020 · Background
    PubMed: PMID 31954465 · NCT06473844 · Inflammation
  51. Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD.
    Prasad PV, Li W, Raj DS, et al. · Kidney Int Rep · 2020 · Background
    PubMed: PMID 30450473 · NCT07175051 (EMPA-CKD) · Albuminuria
  52. Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease.
    Prasad PV, Li LP, Thacker JM, et al. · Am J Nephrol · 2020 · Background
    PubMed: PMID 30669143 · NCT07175051 (EMPA-CKD) · Albuminuria
  53. Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure.
    Pradhan A, Vohra S, Vishwakarma P, et al. · J Family Med Prim Care · 2020 · Background
    PubMed: PMID 31334145 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  54. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Pieske B, Tschöpe C, de Boer RA, et al. · Eur Heart J · 2020 · Background
    PubMed: PMID 31504452 · NCT06249945 (EMPA-PRED) · Heart Failure
  55. Glucagon-like peptide 1 (GLP-1).
    Müller TD, Finan B, Bloom SR, et al. · Mol Metab · 2020 · Background
    PubMed: PMID 31767182 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  56. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus.
    Magkos F, Hjorth MF, Astrup A, et al. · Nat Rev Endocrinol · 2020 · Background
    PubMed: PMID 32690918 · NCT06759922 · Diabetes Mellitus, Type 2
  57. The Growing Epidemic of Diabetes Mellitus.
    Lovic D, Piperidou A, Zografou I, et al. · Curr Vasc Pharmacol · 2020 · Background
    PubMed: PMID 30961501 · NCT06759922 · Diabetes Mellitus, Type 2
  58. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure.
    Kotecha D, Gill SK, Flather MD, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31806133 · NCT06249945 (EMPA-PRED) · Heart Failure
  59. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
    Kim SR, Lee SG, Kim SH, et al. · Nat Commun · 2020 · Background
    PubMed: PMID 32358544 · NCT05512130 · Epilepsy
  60. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K, Cherney DZI, Bozovic A, et al. · Circulation · 2020 · Background
    PubMed: PMID 30773020 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  61. Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.
    Kasztan M, Fox BM, Lebensburger JD, et al. · Blood Adv · 2020 · Background
    PubMed: PMID 31064747 · NCT07175051 (EMPA-CKD) · Albuminuria
  62. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort.
    Karakike E, Kyriazopoulou E, Tsangaris I, et al. · Crit Care · 2020 · Background
    PubMed: PMID 31783881 · NCT06473844 · Inflammation
  63. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
    Johansen NJ, Dejgaard TF, Lund A, et al. · Lancet Diabetes Endocrinol · 2020 · Background
    PubMed: PMID 32135138 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  64. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
    Januzzi JL, Ahmad T, Mulder H, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31466618 · NCT06706791
  65. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes.
    Iannantuoni F, M de Marañon A, Diaz-Morales N, et al. · J Clin Med · 2020 · Background
    PubMed: PMID 31683785 · NCT05610956 · Colitis, Ulcerative
  66. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials.
    Gilbert RE, Thorpe KE · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31050116 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  67. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD Chronic Kidney Disease Collaboration · Lancet · 2020 · Background
    PubMed: PMID 32061315 · NCT06249945 (EMPA-PRED) · Heart Failure
  68. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
    Dominguez Rieg JA, Rieg T · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31081587 · NCT06759922 · Diabetes Mellitus, Type 2
  69. Current State of Pediatric Heart Failure.
    Das BB · Children (Basel) · 2020 · Background
    PubMed: PMID 29958420 · NCT06012266 · Heart Failure
  70. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
    Dale DC, Bolyard AA, Marrero T, et al. · Curr Opin Hematol · 2020 · Background
    PubMed: PMID 30451720 · NCT05078879 · Crohn Disease
  71. Experimental intravascular hemolysis induces hemodynamic and pathological pulmonary hypertension: association with accelerated purine metabolism.
    Bilan VP, Schneider F, Novelli EM, et al. · Pulm Circ · 2020 · Background
    PubMed: PMID 30003836 · NCT07175051 (EMPA-CKD) · Albuminuria
  72. Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Biester T, Kordonouri O, Danne T, et al. · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31081591 · NCT05512130 · Epilepsy
  73. Validation of the corticomedullary difference in magnetic resonance imaging-derived apparent diffusion coefficient for kidney fibrosis detection: a cross-sectional study.
    Berchtold L, Friedli I, Crowe LA, et al. · Nephrol Dial Transplant · 2020 · Background
    PubMed: PMID 30608554 · NCT07175051 (EMPA-CKD) · Albuminuria
  74. Prevalence and risk factors for albuminuria and glomerular hyperfiltration in a large cohort of children with sickle cell anemia.
    Belisário AR, de Almeida JA, Mendes FG, et al. · Am J Hematol · 2020 · Background
    PubMed: PMID 32083326 · NCT07175051 (EMPA-CKD) · Albuminuria
  75. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
    Battelino T, Danne T, Bergenstal RM, et al. · Diabetes Care · 2020 · Background
    PubMed: PMID 31177185 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  76. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease.
    Bansal N, Zelnick L, Bhat Z, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31146814 · NCT06249945 (EMPA-PRED) · Heart Failure
  77. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.
    American Diabetes Association · Diabetes Care · 2020 · Background
    PubMed: PMID 30559228 · NCT04131582 (4T) · Insulin Resistance
  78. Procedural Strategies to Reduce the Incidence of Contrast-Induced Acute Kidney Injury During Percutaneous Coronary Intervention.
    Almendarez M, Gurm HS, Mariani J, et al. · JACC Cardiovasc Interv · 2020 · Background
    PubMed: PMID 31521648 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  79. Duchenne Dilated Cardiomyopathy: Cardiac Management from Prevention to Advanced Cardiovascular Therapies.
    Adorisio R, Mencarelli E, Cantarutti N, et al. · J Clin Med · 2020 · Background
    PubMed: PMID 33019553 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy

2019 (49 papers)

  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD, Raz I, Bonaca MP, et al. · N Engl J Med · 2019 · Trial result
    PubMed: PMID 30415602 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  2. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Striepe K, Jumar A, Ott C, et al. · Circulation · 2019 · Trial result
    PubMed: PMID 28923906 · NCT02471963 · Diabetes Mellitus, Type 2
  3. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
    Mustroph J, Wagemann O, Lücht CM, et al. · ESC Heart Fail · 2019 · Trial result
    PubMed: PMID 30117720 · NCT06103279 · Neoplasms
  4. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite?
    Malone JI, Hansen BC · Pediatr Diabetes · 2019 · Trial result
    PubMed: PMID 30311716 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  5. Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease.
    Hegyi P, Maléth J, Walters JR, et al. · Physiol Rev · 2019 · Trial result
    PubMed: PMID 30067158 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  6. Empagliflozin restores the integrity of the endothelial glycocalyx in vitro.
    Cooper S, Teoh H, Campeau MA, et al. · Mol Cell Biochem · 2019 · Trial result
    PubMed: PMID 31127491 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  7. Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
    Abuosa AM, Elshiekh AH, Qureshi K, et al. · Indian Heart J · 2019 · Trial result
    PubMed: PMID 30595329 · NCT06103279 · Neoplasms
  8. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A, Hanafusa T, Yasui A, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 29766633 · NCT02702011 · Diabetes Mellitus, Type 1
  9. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
    Rosenstock J, Marquard J, Laffel LM, et al. · Diabetes Care · 2019 · Derived
    PubMed: PMID 30287422 · NCT02580591 · Diabetes Mellitus, Type 1
  10. Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
    Muller ME, Pruijm M, Bonny O, et al. · Adv Ther · 2019 · Derived
    PubMed: PMID 29802538 · NCT03093103 (EMPA-REIN) · Kidney Diseases
  11. Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus.
    Lunder M, Janić M, Japelj M, et al. · Cardiovasc Diabetol · 2019 · Derived
    PubMed: PMID 30509271 · NCT03639545 · Diabetes Mellitus, Type 1
  12. Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
    Laffel LMB, Tamborlane WV, Yver A, et al. · Diabet Med · 2019 · Derived
    PubMed: PMID 29655290 · NCT02121483 · Diabetes Mellitus, Type 2
  13. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, et al. · Diabetes Res Clin Pract · 2019 · Derived
    PubMed: PMID 30954510 · NCT03748810
  14. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R, Haneda M, Suzaki K, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 29766636 · NCT02453555 · Diabetes Mellitus, Type 2
  15. Early vascular parameters in the micro- and macrocirculation in type 2 diabetes.
    Kannenkeril D, Bosch A, Harazny J, et al. · Cardiovasc Diabetol · 2019 · Derived
    PubMed: PMID 30231923 · NCT02471963 · Diabetes Mellitus, Type 2
  16. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Kaku K, Haneda M, Tanaka Y, et al. · Diabetes Obes Metab · 2019 · Derived
    PubMed: PMID 30091172 · NCT02489968 · Diabetes Mellitus, Type 2
  17. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus.
    Ferdinand KC, Seman L, Salsali A, et al. · Curr Med Res Opin · 2019 · Derived
    PubMed: PMID 29139301 · NCT02182830 · Diabetes Mellitus, Type 2
  18. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A, Ott C, Jung S, et al. · Cardiovasc Diabetol · 2019 · Derived
    PubMed: PMID 30922297 · NCT02471963 · Diabetes Mellitus, Type 2
  19. Losartan therapy decreases albuminuria with stable glomerular filtration and permselectivity in sickle cell anemia.
    Yee ME, Lane PA, Archer DR, et al. · Blood Cells Mol Dis · 2019 · Background
    PubMed: PMID 28951038 · NCT07175051 (EMPA-CKD) · Albuminuria
  20. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C, Heerspink HJL, Zinman B, et al. · J Am Soc Nephrol · 2019 · Background
    PubMed: PMID 30314978 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  21. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
    Verma S, McMurray JJV · Diabetologia · 2019 · Background
    PubMed: PMID 30132036 · NCT07379788 · Heart Failure
  22. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30415601 · NCT05580510 · Heart Failure
  23. Effect of renin-angiotensin-aldosterone system blocking agents on progression of glomerulopathy in sickle cell disease.
    Thrower A, Ciccone EJ, Maitra P, et al. · Br J Haematol · 2019 · Background
    PubMed: PMID 30460977 · NCT07175051 (EMPA-CKD) · Albuminuria
  24. Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy.
    Thompson IA, Durrani AK, Patel S, et al. · Eye (Lond) · 2019 · Background
    PubMed: PMID 30510234 · NCT04215445 · Diabetes Mellitus
  25. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
    Soga F, Tanaka H, Tatsumi K, et al. · Cardiovasc Diabetol · 2019 · Background
    PubMed: PMID 30296931 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  26. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M, Suzuki K, Kato K, et al. · Diabetes Obes Metab · 2019 · Background
    PubMed: PMID 30178600 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  27. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.
    Selby NM, Blankestijn PJ, Boor P, et al. · Nephrol Dial Transplant · 2019 · Background
    PubMed: PMID 30137584 · NCT07175051 (EMPA-CKD) · Albuminuria
  28. Automated diabetic retinopathy detection using optical coherence tomography angiography: a pilot study.
    Sandhu HS, Eladawi N, Elmogy M, et al. · Br J Ophthalmol · 2019 · Background
    PubMed: PMID 29363532 · NCT04215445 · Diabetes Mellitus
  29. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
    Riddle MC, Cefalu WT · Diabetes Care · 2019 · Background
    PubMed: PMID 30459245 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  30. Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review.
    Pruijm M, Mendichovszky IA, Liss P, et al. · Nephrol Dial Transplant · 2019 · Background
    PubMed: PMID 30137579 · NCT07175051 (EMPA-CKD) · Albuminuria
  31. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V, Jardine MJ, Neal B, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30990260 · NCT07175051 (EMPA-CKD) · Albuminuria
  32. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M, Anker SD, Butler J, et al. · JAMA Cardiol · 2019 · Background
    PubMed: PMID 28768320 · NCT04131582 (4T) · Insulin Resistance
  33. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S, Wagner S, Bollenberg H, et al. · Eur J Heart Fail · 2019 · Background
    PubMed: PMID 30328645 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  34. Arterial spin labelling MRI to measure renal perfusion: a systematic review and statement paper.
    Odudu A, Nery F, Harteveld AA, et al. · Nephrol Dial Transplant · 2019 · Background
    PubMed: PMID 30137581 · NCT07175051 (EMPA-CKD) · Albuminuria
  35. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    McMurray JJV, Solomon SD, Inzucchi SE, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31535829 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  36. Risk factors for retinal microvascular impairment in type 2 diabetic patients without diabetic retinopathy.
    Lee DH, Yi HC, Bae SH, et al. · PLoS One · 2019 · Background
    PubMed: PMID 30092018 · NCT04215445 · Diabetes Mellitus
  37. Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.
    Lebensburger JD, Aban I, Pernell B, et al. · Am J Hematol · 2019 · Background
    PubMed: PMID 30592084 · NCT07175051 (EMPA-CKD) · Albuminuria
  38. GLP-1 Receptor Agonists and Kidney Protection.
    Greco EV, Russo G, Giandalia A, et al. · Medicina (Kaunas) · 2019 · Background
    PubMed: PMID 31159279 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  39. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet · 2019 · Background
    PubMed: PMID 31189511 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  40. Lipid management in patients with chronic kidney disease.
    Ferro CJ, Mark PB, Kanbay M, et al. · Nat Rev Nephrol · 2019 · Background
    PubMed: PMID 30361677 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  41. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW, Lundkvist P, Jansson PA, et al. · Diabetologia · 2019 · Background
    PubMed: PMID 29971527 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  42. Epidemiology of heart failure with preserved ejection fraction.
    Dunlay SM, Roger VL, Redfield MM, et al. · Nat Rev Cardiol · 2019 · Background
    PubMed: PMID 28492288 · NCT06706791
  43. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
    Das SR, Everett BM, Birtcher KK, et al. · J Am Coll Cardiol · 2019 · Background
    PubMed: PMID 30497881 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  44. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C, Lu YP, Yin L, et al. · Kidney Blood Press Res · 2019 · Background
    PubMed: PMID 30939483 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  45. The Relationship of Quantitative Retinal Capillary Network to Kidney Function in Type 2 Diabetes.
    Cheung CY, Tang F, Ng DS, et al. · Am J Kidney Dis · 2019 · Background
    PubMed: PMID 29501263 · NCT04215445 · Diabetes Mellitus
  46. Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper.
    Caroli A, Schneider M, Friedli I, et al. · Nephrol Dial Transplant · 2019 · Background
    PubMed: PMID 30137580 · NCT07175051 (EMPA-CKD) · Albuminuria
  47. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP, Bueser T, Quinlivan R, et al. · Cochrane Database Syst Rev · 2019 · Background
    PubMed: PMID 30326162 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  48. Textbook of gastroenterology.
    Bedine MS · Gastroenterology · 2019 · Background
    PubMed: PMID 10784603 · NCT05610956 · Colitis, Ulcerative
  49. Statistical Model of Optical Coherence Tomography Angiography Parameters That Correlate With Severity of Diabetic Retinopathy.
    Ashraf M, Nesper PL, Jampol LM, et al. · Invest Ophthalmol Vis Sci · 2019 · Background
    PubMed: PMID 30167660 · NCT04215445 · Diabetes Mellitus

2018 (32 papers)

  1. Altered Odor-Induced Brain Activity as an Early Manifestation of Cognitive Decline in Patients With Type 2 Diabetes.
    Zhang Z, Zhang B, Wang X, et al. · Diabetes · 2018 · Trial result
    PubMed: PMID 29500313 · NCT05313529 (LIGHT-MCI) · Diabetes Mellitus, Type 2
  2. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
    Pasquel FJ, Gianchandani R, Rubin DJ, et al. · Lancet Diabetes Endocrinol · 2018 · Trial result
    PubMed: PMID 27964837 · NCT06187285 · Diabetes Mellitus, Type 2
  3. Post-Transplant Diabetes Mellitus After Kidney Transplant in Hispanics and Caucasians Treated with Tacrolimus-Based Immunosuppression.
    Baron PW, Infante S, Peters R, et al. · Ann Transplant · 2018 · Trial result
    PubMed: PMID 28533501 · NCT06098625 (EmLina Renal) · Diabetes Mellitus
  4. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA, Mordi IR, Singh JS, et al. · BMJ Open · 2018 · Derived
    PubMed: PMID 29042392 · NCT03226457 (RECEDE-CHF) · Diabetes Mellitus, Type 2
  5. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL, Cejvanovic V, Kjær LK, et al. · BMJ Open · 2018 · Derived
    PubMed: PMID 28490557 · NCT02890745 (EMPOX) · Diabetes Mellitus, Type 2
  6. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS, Krishan S, Mishra SK, et al. · Diabetes Care · 2018 · Derived
    PubMed: PMID 29895557 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  7. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
    Zhou H, Wang S, Zhu P, et al. · Redox Biol · 2018 · Background
    PubMed: PMID 29306791 · NCT05610956 · Colitis, Ulcerative
  8. Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.
    Yoshizumi H, Ejima T, Nagao T, et al. · Am J Case Rep · 2018 · Background
    PubMed: PMID 29670074 · NCT04215445 · Diabetes Mellitus
  9. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine.
    Weisbord SD, Gallagher M, Jneid H, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29130810 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  10. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.
    Venkatesh B, Finfer S, Cohen J, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29347874 · NCT06473844 · Inflammation
  11. Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.
    Sviklāne L, Olmane E, Dzērve Z, et al. · J Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 28464337 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  12. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol · 2018 · Background
    PubMed: PMID 29397376 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  13. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P, Avogaro A, Bonora E, et al. · Int J Cardiol · 2018 · Background
    PubMed: PMID 28395981 · NCT03933956 ((MEDiaN)) · Diabetic Nephropathies
  14. Glucose transporter expression in the human colon.
    Merigo F, Brandolese A, Facchin S, et al. · World J Gastroenterol · 2018 · Background
    PubMed: PMID 29467549 · NCT05610956 · Colitis, Ulcerative
  15. New markers of urinary tract infection.
    Masajtis-Zagajewska A, Nowicki M · Clin Chim Acta · 2018 · Background
    PubMed: PMID 28622967 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  16. Intravoxel incoherent motion diffusion-weighted imaging for the assessment of renal fibrosis of chronic kidney disease: A preliminary study.
    Mao W, Zhou J, Zeng M, et al. · Magn Reson Imaging · 2018 · Background
    PubMed: PMID 29217491 · NCT07175051 (EMPA-CKD) · Albuminuria
  17. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
    Lundkvist P, Pereira MJ, Katsogiannos P, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 28345814 · NCT04131582 (4T) · Insulin Resistance
  18. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Liu J, Li L, Li S, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28588220 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  19. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
    Inzucchi SE, Zinman B, Fitchett D, et al. · Diabetes Care · 2018 · Background
    PubMed: PMID 29203583 · NCT04203927 (EJB051) · Insulin Resistance
  20. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
    Held C, White HD, Stewart RAH, et al. · J Am Heart Assoc · 2018 · Background
    PubMed: PMID 29066452 · NCT05911724 · Heart Failure
  21. Effect of Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance.
    González-Heredia T, Hernández-Corona DM, González-Ortiz M, et al. · Diabetes Technol Ther · 2018 · Background
    PubMed: PMID 28581818 · NCT04131582 (4T) · Insulin Resistance
  22. Survival in adults with sickle cell disease in a high-income setting.
    Gardner K, Douiri A, Drasar E, et al. · Blood · 2018 · Background
    PubMed: PMID 27439910 · NCT07175051 (EMPA-CKD) · Albuminuria
  23. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time.
    Fisher L, Hessler D, Polonsky W, et al. · J Diabetes Complications · 2018 · Background
    PubMed: PMID 27118163 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  24. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
    Del Prato S, Rosenstock J, Garcia-Sanchez R, et al. · Diabetes Obes Metab · 2018 · Background
    PubMed: PMID 29446523 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  25. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
    Cho NH, Shaw JE, Karuranga S, et al. · Diabetes Res Clin Pract · 2018 · Background
    PubMed: PMID 29496507 · NCT04215445 · Diabetes Mellitus
  26. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI, Zinman B, Inzucchi SE, et al. · Lancet Diabetes Endocrinol · 2018 · Background
    PubMed: PMID 28666775 · NCT07175051 (EMPA-CKD) · Albuminuria
  27. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Chalasani N, Younossi Z, Lavine JE, et al. · Hepatology · 2018 · Background
    PubMed: PMID 28714183 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  28. Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.
    Budts W, Roos-Hesselink J, Rädle-Hurst T, et al. · Eur Heart J · 2018 · Background
    PubMed: PMID 26787434 · NCT05580510 · Heart Failure
  29. Use of Radiocontrast Agents in CKD and ESRD.
    Bahrainwala JZ, Leonberg-Yoo AK, Rudnick MR, et al. · Semin Dial · 2018 · Background
    PubMed: PMID 28382626 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  30. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018.
    American Diabetes Association · Diabetes Care · 2018 · Background
    PubMed: PMID 29222381 · NCT04215445 · Diabetes Mellitus
  31. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
    Ahmann AJ, Capehorn M, Charpentier G, et al. · Diabetes Care · 2018 · Background
    PubMed: PMID 29246950 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  32. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.
    Abenavoli L, Greco M, Milic N, et al. · Nutrients · 2018 · Background
    PubMed: PMID 28805669 · NCT05605158 · Non-alcoholic Fatty Liver Disease

2017 (37 papers)

  1. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Mahaffey KW, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28605608 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  2. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G, Nabati M, Faghihinia M, et al. · Cardiovasc Toxicol · 2017 · Trial result
    PubMed: PMID 27003392 · NCT06103279 · Neoplasms
  3. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P, Zambon A, Rossato M, et al. · Diabetes Care · 2017 · Trial result
    PubMed: PMID 27440829 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  4. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E, Meier JJ, Vangen B, et al. · Diabetes Care · 2017 · Derived
    PubMed: PMID 27913576 · NCT01734785 · Diabetes Mellitus, Type 2
  5. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
    Hadjadj S, Rosenstock J, Meinicke T, et al. · Diabetes Care · 2017 · Derived
    PubMed: PMID 27493136 · NCT01719003 · Diabetes Mellitus, Type 2
  6. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
    Famulla S, Pieber TR, Eilbracht J, et al. · Diabetes Technol Ther · 2017 · Derived
    PubMed: PMID 27929674 · NCT01969747 · Diabetes Mellitus, Type 1
  7. Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.
    Al-Jobori H, Daniele G, Cersosimo E, et al. · Diabetes · 2017 · Derived
    PubMed: PMID 28428225 · NCT01867307 · Diabetes Mellitus, Type 2
  8. Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.
    Abdul-Ghani M, Al Jobori H, Daniele G, et al. · Diabetes · 2017 · Derived
    PubMed: PMID 28611037 · NCT01867307 · Diabetes Mellitus, Type 2
  9. mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease.
    Wang J, Tran J, Wang H, et al. · Br J Haematol · 2017 · Background
    PubMed: PMID 27030515 · NCT07175051 (EMPA-CKD) · Albuminuria
  10. Optical Coherence Tomographic Angiography in Type 2 Diabetes and Diabetic Retinopathy.
    Ting DSW, Tan GSW, Agrawal R, et al. · JAMA Ophthalmol · 2017 · Background
    PubMed: PMID 28208170 · NCT04215445 · Diabetes Mellitus
  11. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.
    Ter Maaten JM, Damman K, Verhaar MC, et al. · Eur J Heart Fail · 2017 · Background
    PubMed: PMID 26861140 · NCT06249945 (EMPA-PRED) · Heart Failure
  12. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A, Shimabukuro M, Okada Y, et al. · Cardiovasc Diabetol · 2017 · Background
    PubMed: PMID 28403850 · NCT06313008 · Diabetes Mellitus, Type 2
  13. Increased risk of glomerular hyperfiltration in subjects with impaired glucose tolerance and newly diagnosed diabetes.
    Sun ZJ, Yang YC, Wu JS, et al. · Nephrol Dial Transplant · 2017 · Background
    PubMed: PMID 26610595 · NCT04131582 (4T) · Insulin Resistance
  14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH, et al. · Clin Ther · 2017 · Background
    PubMed: PMID 27210264 · NCT06313008 · Diabetes Mellitus, Type 2
  15. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
    Sattar N, McLaren J, Kristensen SL, et al. · Diabetologia · 2017 · Background
    PubMed: PMID 27112340 · NCT03151343 (SIMPLE)
  16. Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases.
    Regueiro M, Greer JB, Szigethy E, et al. · Gastroenterology · 2017 · Background
    PubMed: PMID 27816599 · NCT05610956 · Colitis, Ulcerative
  17. Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial.
    Quinn CT, Saraf SL, Gordeuk VR, et al. · Am J Hematol · 2017 · Background
    PubMed: PMID 28589652 · NCT07175051 (EMPA-CKD) · Albuminuria
  18. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.
    Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. · Diabetes Res Clin Pract · 2017 · Background
    PubMed: PMID 28437734 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  19. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Matthews DR, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 29166232 · NCT04203927 (EJB051) · Insulin Resistance
  20. Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.
    Naing S, Poliyedath A, Khandelwal S, et al. · Postgrad Med · 2017 · Background
    PubMed: PMID 27701934 · NCT06313008 · Diabetes Mellitus, Type 2
  21. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S, Alloju S, Henry RR, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27289124 · NCT03151343 (SIMPLE)
  22. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
    Mathieu C, Zinman B, Hemmingsson JU, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27506222 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  23. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    Mann JFE, Ørsted DD, Brown-Frandsen K, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28854085 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  24. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I · Endocr Pract · 2017 · Background
    PubMed: PMID 28332871 · NCT04131582 (4T) · Insulin Resistance
  25. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D, Wang T, Shen S, et al. · Diabetes Obes Metab · 2017 · Background
    PubMed: PMID 27862830 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  26. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.
    Lee YH, Kim JH, Kim SR, et al. · J Korean Med Sci · 2017 · Background
    PubMed: PMID 27914133 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  27. Metrics for glycaemic control - from HbA1c to continuous glucose monitoring.
    Kovatchev BP · Nat Rev Endocrinol · 2017 · Background
    PubMed: PMID 28304392 · NCT04203927 (EJB051) · Insulin Resistance
  28. Non-alcoholic fatty liver disease and diabetes.
    Hazlehurst JM, Woods C, Marjot T, et al. · Metabolism · 2017 · Background
    PubMed: PMID 26856933 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  29. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Ferrannini E, Mark M, Mayoux E, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27289126 · NCT03151343 (SIMPLE)
  30. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E, Baldi S, Frascerra S, et al. · Diabetes · 2017 · Background
    PubMed: PMID 26861783 · NCT05512130 · Epilepsy
  31. [Not Available].
    Feres F, Costa RA, Siqueira D, et al. · Arq Bras Cardiol · 2017 · Background
    PubMed: PMID 28792984 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  32. Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.
    Chang YK, Choi H, Jeong JY, et al. · PLoS One · 2017 · Background
    PubMed: PMID 27391020 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  33. Non-proteinuric rather than proteinuric renal diseases are the leading cause of end-stage kidney disease.
    Bolignano D, Zoccali C · Nephrol Dial Transplant · 2017 · Background
    PubMed: PMID 28340010 · NCT04215445 · Diabetes Mellitus
  34. Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β-Thalassemia.
    Bellanti F, Di Iorio VL, Danhof M, et al. · J Clin Pharmacol · 2017 · Background
    PubMed: PMID 26785826 · NCT06012266 · Heart Failure
  35. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A, Ceccarelli S, Panera N, et al. · PLoS One · 2017 · Background
    PubMed: PMID 23840612 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  36. Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
    Ahrén B, Hirsch IB, Pieber TR, et al. · Diabetes Care · 2017 · Background
    PubMed: PMID 27493132 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  37. Metabolic aspects of adult patients with nonalcoholic fatty liver disease.
    Abenavoli L, Milic N, Di Renzo L, et al. · World J Gastroenterol · 2017 · Background
    PubMed: PMID 27610012 · NCT05605158 · Non-alcoholic Fatty Liver Disease

2016 (26 papers)

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Lachin JM, Inzucchi SE, et al. · N Engl J Med · 2016 · Trial result
    PubMed: PMID 26981940 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA, Tsapas A · N Engl J Med · 2016 · Trial result
    PubMed: PMID 26981941 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  3. Non-invasive quantification of hepatic steatosis in living, related liver donors using dual-echo Dixon imaging and single-voxel proton spectroscopy.
    Krishan S, Jain D, Bathina Y, et al. · Clin Radiol · 2016 · Trial result
    PubMed: PMID 26555703 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  4. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, et al. · Circulation · 2016 · Trial result
    PubMed: PMID 27470878 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  5. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
    Nishimura R, Tanaka Y, Koiwai K, et al. · Cardiovasc Diabetol · 2016 · Derived
    PubMed: PMID 25633683 · NCT01947855 · Diabetes Mellitus, Type 2
  6. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C, Inzucchi SE, Lachin JM, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27299675 · NCT03173963 · Diabetes Mellitus, Type 2
  7. Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes.
    von Scholten BJ, Hasbak P, Christensen TE, et al. · Diabetologia · 2016 · Background
    PubMed: PMID 26526662 · NCT03151343 (SIMPLE)
  8. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
    Udell JA, Cavender MA, Bhatt DL, et al. · Lancet Diabetes Endocrinol · 2016 · Background
    PubMed: PMID 25791290 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  9. Chronic Heart Failure in Congenital Heart Disease: A Scientific Statement From the American Heart Association.
    Stout KK, Broberg CS, Book WM, et al. · Circulation · 2016 · Background
    PubMed: PMID 26787728 · NCT05580510 · Heart Failure
  10. Extra-glycaemic properties of empagliflozin.
    Solini A · Diabetes Metab Res Rev · 2016 · Background
    PubMed: PMID 25994513 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  11. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
    Singer M, Deutschman CS, Seymour CW, et al. · JAMA · 2016 · Background
    PubMed: PMID 26903338 · NCT06473844 · Inflammation
  12. Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.
    Saraf SL, Zhang X, Shah B, et al. · Haematologica · 2016 · Background
    PubMed: PMID 26206798 · NCT07175051 (EMPA-CKD) · Albuminuria
  13. Prevalence of heart failure in Australia: a systematic review.
    Sahle BW, Owen AJ, Mutowo MP, et al. · BMC Cardiovasc Disord · 2016 · Background
    PubMed: PMID 26852410 · NCT05129722
  14. Microalbuminuria: target for renoprotective therapy PRO.
    Roscioni SS, Lambers Heerspink HJ, de Zeeuw D, et al. · Kidney Int · 2016 · Background
    PubMed: PMID 24759154 · NCT07175051 (EMPA-CKD) · Albuminuria
  15. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP, Daniels GH, Brown-Frandsen K, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27295427 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  16. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Marso SP, Bain SC, Consoli A, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27633186 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  17. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View.
    Lambers Heerspink HJ, Gansevoort RT · Clin J Am Soc Nephrol · 2016 · Background
    PubMed: PMID 25887073 · NCT07175051 (EMPA-CKD) · Albuminuria
  18. Heart rate variability density analysis (Dyx) for identification of appropriate implantable cardioverter defibrillator recipients among elderly patients with acute myocardial infarction and left ventricular systolic dysfunction.
    Jørgensen RM, Levitan J, Halevi Z, et al. · Europace · 2016 · Background
    PubMed: PMID 25755288 · NCT03151343 (SIMPLE)
  19. Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes.
    Jojima T, Tomotsune T, Iijima T, et al. · Diabetol Metab Syndr · 2016 · Background
    PubMed: PMID 27462372 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  20. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
    Jhund PS, Anand IS, Komajda M, et al. · Eur J Heart Fail · 2016 · Background
    PubMed: PMID 25921853 · NCT03151343 (SIMPLE)
  21. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.
    Hasenfuß G, Hayward C, Burkhoff D, et al. · Lancet · 2016 · Background
    PubMed: PMID 27025436 · NCT03151343 (SIMPLE)
  22. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
    Ferrannini G, Hach T, Crowe S, et al. · Diabetes Care · 2016 · Background
    PubMed: PMID 26180105 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  23. Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease.
    El-Haggar SM, Mostafa TM · Hepatol Int · 2016 · Background
    PubMed: PMID 25956613 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  24. Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.
    Du Q, Wang YJ, Yang S, et al. · Adv Ther · 2016 · Background
    PubMed: PMID 25388240 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  25. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review.
    Colman RJ, Rubin DT · Intest Res · 2016 · Background
    PubMed: PMID 27433141 · NCT05610956 · Colitis, Ulcerative
  26. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
    Chilton R, Tikkanen I, Cannon CP, et al. · Diabetes Obes Metab · 2016 · Background
    PubMed: PMID 26343814 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2

2015 (30 papers)

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B, Wanner C, Lachin JM, et al. · N Engl J Med · 2015 · Trial result
    PubMed: PMID 26378978 · NCT06706791
  2. Cardiovascular morbidity and mortality after kidney transplantation.
    Stoumpos S, Jardine AG, Mark PB, et al. · Transpl Int · 2015 · Trial result
    PubMed: PMID 25081992 · NCT04906213 (CREST-KT) · Diabetes Mellitus, Type 2
  3. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions.
    Sharif A, Hecking M, de Vries AP, et al. · Am J Transplant · 2015 · Trial result
    PubMed: PMID 25307034 · NCT06095492 (EmLinaRenal) · Diabetes Mellitus
  4. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
    Cardinale D, Colombo A, Bacchiani G, et al. · Circulation · 2015 · Trial result
    PubMed: PMID 25948538 · NCT06103279 · Neoplasms
  5. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
    Broeyer FJ, Osanto S, Suzuki J, et al. · Br J Clin Pharmacol · 2015 · Trial result
    PubMed: PMID 24844787 · NCT06103279 · Neoplasms
  6. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
    Lamos EM, Younk LM, Davis SN, et al. · Expert Opin Investig Drugs · 2015 · Derived
    PubMed: PMID 24746173 · NCT01969747 · Diabetes Mellitus, Type 1
  7. Hyperfiltration is associated with the development of microalbuminuria in patients with sickle cell anemia.
    Vazquez B, Shah B, Zhang X, et al. · Am J Hematol · 2015 · Background
    PubMed: PMID 25132221 · NCT07175051 (EMPA-CKD) · Albuminuria
  8. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
    Tikkanen I, Narko K, Zeller C, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 25271206 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  9. SGLT inhibitors in management of diabetes.
    Tahrani AA, Barnett AH, Bailey CJ, et al. · Lancet Diabetes Endocrinol · 2015 · Background
    PubMed: PMID 24622320 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  10. Standards of medical care in diabetes--2015: summary of revisions.
    Diabetes Care · 2015 · Background
    PubMed: PMID 25537706 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  11. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M, Cherney DZ · Curr Opin Nephrol Hypertens · 2015 · Background
    PubMed: PMID 25470017 · NCT04215445 · Diabetes Mellitus
  12. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
    Sha S, Polidori D, Heise T, et al. · Diabetes Obes Metab · 2015 · Background
    PubMed: PMID 24939043 · NCT03132181 (EMPA) · Diabetes Mellitus, Type 2
  13. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Roden M, Weng J, Eilbracht J, et al. · Lancet Diabetes Endocrinol · 2015 · Background
    PubMed: PMID 24622369 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  14. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M, Andersen KR, Zeller C, et al. · Lancet Diabetes Endocrinol · 2015 · Background
    PubMed: PMID 24948511 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  15. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
    Oelze M, Kröller-Schön S, Welschof P, et al. · PLoS One · 2015 · Background
    PubMed: PMID 25402275 · NCT03151343 (SIMPLE)
  16. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management.
    Nitzan O, Elias M, Chazan B, et al. · Diabetes Metab Syndr Obes · 2015 · Background
    PubMed: PMID 25759592 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  17. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
    Lin B, Koibuchi N, Hasegawa Y, et al. · Cardiovasc Diabetol · 2015 · Background
    PubMed: PMID 25344694 · NCT03151343 (SIMPLE)
  18. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS, Seshiah V, Swallow R, et al. · Diabetes Obes Metab · 2015 · Background
    PubMed: PMID 23906415 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  19. Mitochondrial dysfunction and respiratory chain defects in a rodent model of methotrexate-induced enteritis.
    Kolli VK, Natarajan K, Isaac B, et al. · Hum Exp Toxicol · 2015 · Background
    PubMed: PMID 24347301 · NCT06641128 · Arthritis, Rheumatoid
  20. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
    Kim NH, Yu T, Lee DH, et al. · Biomed Res Int · 2015 · Background
    PubMed: PMID 25140306 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  21. Interaction between the pentose phosphate pathway and gluconeogenesis from glycerol in the liver.
    Jin ES, Sherry AD, Malloy CR, et al. · J Biol Chem · 2015 · Background
    PubMed: PMID 25288790 · NCT02833415 · Diabetes Mellitus
  22. Associations of prediabetes with all-cause and cardiovascular mortality: a meta-analysis.
    Huang Y, Cai X, Chen P, et al. · Ann Med · 2015 · Background
    PubMed: PMID 25230915 · NCT04131582 (4T) · Insulin Resistance
  23. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.
    Heerspink HJ, Kröpelin TF, Hoekman J, et al. · J Am Soc Nephrol · 2015 · Background
    PubMed: PMID 25421558 · NCT07175051 (EMPA-CKD) · Albuminuria
  24. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
    Häring HU, Merker L, Seewaldt-Becker E, et al. · Diabetes Care · 2015 · Background
    PubMed: PMID 23963895 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  25. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
    Green JB, Bethel MA, Armstrong PW, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26052984 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  26. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA, Wright EM, Vallon V, et al. · Diab Vasc Dis Res · 2015 · Background
    PubMed: PMID 25616707 · NCT03151343 (SIMPLE)
  27. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
    Eng C, Kramer CK, Zinman B, et al. · Lancet · 2015 · Background
    PubMed: PMID 25220191 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  28. Fructose ingestion acutely stimulates circulating FGF21 levels in humans.
    Dushay JR, Toschi E, Mitten EK, et al. · Mol Metab · 2015 · Background
    PubMed: PMID 25685689 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  29. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
    de Wit HM, Vervoort GM, Jansen HJ, et al. · Diabetologia · 2015 · Background
    PubMed: PMID 24947583 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  30. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes.
    Aubert CE, Michel PL, Gillery P, et al. · Diabetes Metab Res Rev · 2015 · Background
    PubMed: PMID 24449227 · NCT03151343 (SIMPLE)

2014 (36 papers)

  1. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
    Soliman AR, Fathy A, Khashab S, et al. · Exp Clin Transplant · 2014 · Trial result
    PubMed: PMID 24344941 · NCT06095492 (EmLinaRenal) · Diabetes Mellitus
  2. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J, Seman LJ, Jelaska A, et al. · Diabetes Obes Metab · 2014 · Trial result
    PubMed: PMID 23906374 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  3. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.
    Kaya MG, Ozkan M, Gunebakmaz O, et al. · Int J Cardiol · 2014 · Trial result
    PubMed: PMID 22727976 · NCT06103279 · Neoplasms
  4. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.
    Haidinger M, Werzowa J, Hecking M, et al. · Am J Transplant · 2014 · Trial result
    PubMed: PMID 24279801 · NCT06095492 (EmLinaRenal) · Diabetes Mellitus
  5. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E, Seman L, Seewaldt-Becker E, et al. · Diabetes Obes Metab · 2014 · Trial result
    PubMed: PMID 23398530 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  6. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.
    Macha S, Koenen R, Sennewald R, et al. · Clin Ther · 2014 · Derived
    PubMed: PMID 24491572 · NCT01634100
  7. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V, Gerasimova M, Rose MA, et al. · Am J Physiol Renal Physiol · 2014 · Background
    PubMed: PMID 24226524 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  8. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A, Kurosaki E, Yokono M, et al. · Eur J Pharmacol · 2014 · Background
    PubMed: PMID 23707905 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  9. The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia.
    Straznicky NE, Lambert EA, Grima MT, et al. · Obesity (Silver Spring) · 2014 · Background
    PubMed: PMID 23997009 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  10. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.
    Saraf SL, Zhang X, Kanias T, et al. · Br J Haematol · 2014 · Background
    PubMed: PMID 24329963 · NCT07175051 (EMPA-CKD) · Albuminuria
  11. New-onset atrial fibrillation predicts malignant arrhythmias in post-myocardial infarction patients--a Cardiac Arrhythmias and RIsk Stratification after acute Myocardial infarction (CARISMA) substudy.
    Ruwald AC, Bloch Thomsen PE, Gang U, et al. · Am Heart J · 2014 · Background
    PubMed: PMID 24176441 · NCT03151343 (SIMPLE)
  12. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study.
    Rubin DT, Huo D, Kinnucan JA, et al. · Clin Gastroenterol Hepatol · 2014 · Background
    PubMed: PMID 23872237 · NCT05610956 · Colitis, Ulcerative
  13. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J, Jelaska A, Frappin G, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 24929430 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  14. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
    Neeland IJ, Ayers CR, Rohatgi AK, et al. · Obesity (Silver Spring) · 2014 · Background
    PubMed: PMID 23687099 · NCT02833415 · Diabetes Mellitus
  15. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A, Solis-Herrera C, Daniele G, et al. · J Clin Invest · 2014 · Background
    PubMed: PMID 24463448 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  16. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
    McMurray JJ, Packer M, Desai AS, et al. · N Engl J Med · 2014 · Background
    PubMed: PMID 25176015 · NCT07379788 · Heart Failure
  17. [Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
    Mauricio D · Med Clin (Barc) · 2014 · Background
    PubMed: PMID 24444522 · NCT03132181 (EMPA) · Diabetes Mellitus, Type 2
  18. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
    Madsbad S · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 23617798 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  19. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal.
    Machado MV, Cortez-Pinto H · J Hepatol · 2014 · Background
    PubMed: PMID 23183525 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  20. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S, Mattheus M, Halabi A, et al. · Diabetes Obes Metab · 2014 · Background
    PubMed: PMID 23859488 · NCT06249932 (EMPA-RRED) · Kidney Failure, Chronic
  21. Prevention of vitamin D insufficiency in Switzerland: a never-ending story.
    Lava SA, Simonetti GD, Bianchetti AA, et al. · Int J Pharm · 2014 · Background
    PubMed: PMID 24216246 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  22. SGLT2 inhibitors in the treatment of type 2 diabetes.
    Hasan FM, Alsahli M, Gerich JE, et al. · Diabetes Res Clin Pract · 2014 · Background
    PubMed: PMID 24735709 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  23. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
    Häring HU, Merker L, Seewaldt-Becker E, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 24722494 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  24. Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor.
    Fu Z, Zhao L, Aylor KW, et al. · Hypertension · 2014 · Background
    PubMed: PMID 24711523 · NCT04203927 (EJB051) · Insulin Resistance
  25. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    Ferrannini E, Muscelli E, Frascerra S, et al. · J Clin Invest · 2014 · Background
    PubMed: PMID 24463454 · NCT03933956 ((MEDiaN)) · Diabetic Nephropathies
  26. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt.
    Esmat S, El Nady M, Elfekki M, et al. · World J Gastroenterol · 2014 · Background
    PubMed: PMID 24574754 · NCT05610956 · Colitis, Ulcerative
  27. Factors associated with survival in a contemporary adult sickle cell disease cohort.
    Elmariah H, Garrett ME, De Castro LM, et al. · Am J Hematol · 2014 · Background
    PubMed: PMID 24478166 · NCT07175051 (EMPA-CKD) · Albuminuria
  28. Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease.
    Eisen A, Benderly M, Behar S, et al. · Am Heart J · 2014 · Background
    PubMed: PMID 24766981 · NCT05911724 · Heart Failure
  29. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
    DeFronzo RA, Hompesch M, Kasichayanula S, et al. · Diabetes Care · 2014 · Background
    PubMed: PMID 23735727 · NCT03132181 (EMPA) · Diabetes Mellitus, Type 2
  30. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study.
    Darbari DS, Wang Z, Kwak M, et al. · PLoS One · 2014 · Background
    PubMed: PMID 24224021 · NCT07175051 (EMPA-CKD) · Albuminuria
  31. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
    Cherney DZ, Perkins BA, Soleymanlou N, et al. · Cardiovasc Diabetol · 2014 · Background
    PubMed: PMID 24475922 · NCT03132181 (EMPA) · Diabetes Mellitus, Type 2
  32. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Mithal A, Manassie J, et al. · Lancet Diabetes Endocrinol · 2014 · Background
    PubMed: PMID 24795251 · NCT05164263 (EASE) · Diabetes Mellitus, Type 2
  33. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations.
    Banka S, Newman WG · Orphanet J Rare Dis · 2014 · Background
    PubMed: PMID 23758768 · NCT05078879 · Crohn Disease
  34. The glomerulopathy of sickle cell disease.
    Ataga KI, Derebail VK, Archer DR, et al. · Am J Hematol · 2014 · Background
    PubMed: PMID 24840607 · NCT07175051 (EMPA-CKD) · Albuminuria
  35. Clinical profile of urinary tract infections in diabetics and non-diabetics.
    Aswani SM, Chandrashekar U, Shivashankara K, et al. · Australas Med J · 2014 · Background
    PubMed: PMID 24567764 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  36. Determining glomerular filtration rate in homozygous sickle cell disease: utility of serum creatinine based estimating equations.
    Asnani MR, Lynch O, Reid ME, et al. · PLoS One · 2014 · Background
    PubMed: PMID 23894560 · NCT07175051 (EMPA-CKD) · Albuminuria

2013 (17 papers)

  1. Bile acid metabolism and signaling.
    Chiang JY · Compr Physiol · 2013 · Trial result
    PubMed: PMID 23897684 · NCT07120828 (CYP8B1-SGLT2-T) · Diabetes Mellitus, Type 2
  2. Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin delivery.
    Zhao L, Chai W, Fu Z, et al. · Circ Res · 2013 · Background
    PubMed: PMID 23459195 · NCT04203927 (EJB051) · Insulin Resistance
  3. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
    Willemsen S, Hartog JW, van Veldhuisen DJ, et al. · Am Heart J · 2013 · Background
    PubMed: PMID 23137505 · NCT03151343 (SIMPLE)
  4. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
    Vasilakou D, Karagiannis T, Athanasiadou E, et al. · Ann Intern Med · 2013 · Background
    PubMed: PMID 24026259 · NCT03933956 ((MEDiaN)) · Diabetic Nephropathies
  5. The relation of glucose metabolism to left ventricular mass and function and sympathetic nervous system activity in obese subjects with metabolic syndrome.
    Straznicky NE, Grima MT, Sari CI, et al. · J Clin Endocrinol Metab · 2013 · Background
    PubMed: PMID 23271752 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  6. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.
    Sharma K, Karl B, Mathew AV, et al. · J Am Soc Nephrol · 2013 · Background
    PubMed: PMID 23949796 · NCT03933956 ((MEDiaN)) · Diabetic Nephropathies
  7. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study.
    Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, et al. · BMC Nephrol · 2013 · Background
    PubMed: PMID 23433046 · NCT04215445 · Diabetes Mellitus
  8. Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations.
    Papaioannou V, Pneumatikos I, Maglaveras N, et al. · Front Physiol · 2013 · Background
    PubMed: PMID 23847549 · NCT05911724 · Heart Failure
  9. Prognostic interplay of coronary artery calcification and underlying vascular dysfunction in patients with suspected coronary artery disease.
    Naya M, Murthy VL, Foster CR, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23524053 · NCT03151343 (SIMPLE)
  10. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).
    Moussa ID, Klein LW, Shah B, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 24135581 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  11. Tissue specificity in fasting glucose utilization in slightly obese diabetic patients submitted to bariatric surgery.
    Morbelli S, Marini C, Adami GF, et al. · Obesity (Silver Spring) · 2013 · Background
    PubMed: PMID 23404920 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  12. Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial.
    Lima EG, Hueb W, Garcia RM, et al. · Am Heart J · 2013 · Background
    PubMed: PMID 23895807 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  13. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults.
    Lewis DA, Brown R, Williams J, et al. · Front Cell Infect Microbiol · 2013 · Background
    PubMed: PMID 23967406 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  14. Sodium glucose cotransporter 2 and the diabetic kidney.
    Komala MG, Panchapakesan U, Pollock C, et al. · Curr Opin Nephrol Hypertens · 2013 · Background
    PubMed: PMID 23042029 · NCT04215445 · Diabetes Mellitus
  15. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010.
    Jess T, Frisch M, Simonsen J, et al. · Clin Gastroenterol Hepatol · 2013 · Background
    PubMed: PMID 23022699 · NCT05610956 · Colitis, Ulcerative
  16. Global left ventricular longitudinal strain is closely associated with increased neurohormonal activation after acute myocardial infarction in patients with both reduced and preserved ejection fraction: a two-dimensional speckle tracking study.
    Ersbøll M, Valeur N, Mogensen UM, et al. · Eur J Heart Fail · 2013 · Background
    PubMed: PMID 22753861 · NCT03151343 (SIMPLE)
  17. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry.
    Dorbala S, Di Carli MF, Beanlands RS, et al. · J Am Coll Cardiol · 2013 · Background
    PubMed: PMID 23219297 · NCT03151343 (SIMPLE)

2012 (15 papers)

  1. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.
    Umpierrez GE, Hellman R, Korytkowski MT, et al. · J Clin Endocrinol Metab · 2012 · Trial result
    PubMed: PMID 22223765 · NCT06187285 · Diabetes Mellitus, Type 2
  2. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial.
    Le TA, Chen J, Changchien C, et al. · Hepatology · 2012 · Trial result
    PubMed: PMID 22431131 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  3. Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks.
    Yu L, Buysse DJ, Germain A, et al. · Behav Sleep Med · 2012 · Background
    PubMed: PMID 22250775 · NCT05081219 · Alzheimer Disease
  4. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat.
    Thomson SC, Rieg T, Miracle C, et al. · Am J Physiol Regul Integr Comp Physiol · 2012 · Background
    PubMed: PMID 21940401 · NCT07175051 (EMPA-CKD) · Albuminuria
  5. Incretin-based therapies.
    Stonehouse AH, Darsow T, Maggs DG, et al. · J Diabetes · 2012 · Background
    PubMed: PMID 21707956 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  6. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study.
    Rossano JW, Kim JJ, Decker JA, et al. · J Card Fail · 2012 · Background
    PubMed: PMID 22633303 · NCT06012266 · Heart Failure
  7. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults.
    Neeland IJ, Turer AT, Ayers CR, et al. · JAMA · 2012 · Background
    PubMed: PMID 22990274 · NCT02833415 · Diabetes Mellitus
  8. High one year mortality in adults with sickle cell disease and end-stage renal disease.
    McClellan AC, Luthi JC, Lynch JR, et al. · Br J Haematol · 2012 · Background
    PubMed: PMID 22967259 · NCT07175051 (EMPA-CKD) · Albuminuria
  9. Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels.
    Marini MA, Succurro E, Frontoni S, et al. · Diabetes Care · 2012 · Background
    PubMed: PMID 22357182 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  10. Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease.
    Gladwin MT, Kanias T, Kim-Shapiro DB, et al. · J Clin Invest · 2012 · Background
    PubMed: PMID 22446184 · NCT07175051 (EMPA-CKD) · Albuminuria
  11. Association between hemolysis and albuminuria in adults with sickle cell anemia.
    Day TG, Drasar ER, Fulford T, et al. · Haematologica · 2012 · Background
    PubMed: PMID 21993677 · NCT07175051 (EMPA-CKD) · Albuminuria
  12. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S, Baker LD, Montine TJ, et al. · Arch Neurol · 2012 · Background
    PubMed: PMID 21911655 · NCT05081219 · Alzheimer Disease
  13. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
    Chalasani N, Younossi Z, Lavine JE, et al. · Hepatology · 2012 · Background
    PubMed: PMID 22488764 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  14. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
    Bolinder J, Ljunggren Ö, Kullberg J, et al. · J Clin Endocrinol Metab · 2012 · Background
    PubMed: PMID 22238392 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  15. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Albert MS, DeKosky ST, Dickson D, et al. · Alzheimers Dement · 2012 · Background
    PubMed: PMID 21514249 · NCT05081219 · Alzheimer Disease

2011 (25 papers)

  1. Quantification of liver fat with magnetic resonance imaging.
    Reeder SB, Sirlin CB · Magn Reson Imaging Clin N Am · 2011 · Trial result
    PubMed: PMID 21094444 · NCT02686476 (E-LIFT) · Non-alcoholic Fatty Liver Disease
  2. Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα.
    Wang N, Ko SH, Chai W, et al. · Am J Physiol Endocrinol Metab · 2011 · Background
    PubMed: PMID 20978231 · NCT04203927 (EJB051) · Insulin Resistance
  3. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations.
    Verhaert D, Richards K, Rafael-Fortney JA, et al. · Circ Cardiovasc Imaging · 2011 · Background
    PubMed: PMID 21245364 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  4. Long-term persistence of hormonal adaptations to weight loss.
    Sumithran P, Prendergast LA, Delbridge E, et al. · N Engl J Med · 2011 · Background
    PubMed: PMID 22029981 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  5. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease.
    Saraf S, Farooqui M, Infusino G, et al. · Br J Haematol · 2011 · Background
    PubMed: PMID 21418176 · NCT07175051 (EMPA-CKD) · Albuminuria
  6. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.
    Sano M, Raman R, Emond J, et al. · Alzheimer Dis Assoc Disord · 2011 · Background
    PubMed: PMID 20921876 · NCT05081219 · Alzheimer Disease
  7. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes.
    Renko M, Tapanainen P, Tossavainen P, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 20937688 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  8. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes.
    Penno G, Solini A, Bonora E, et al. · J Hypertens · 2011 · Background
    PubMed: PMID 21738053 · NCT04215445 · Diabetes Mellitus
  9. No-reflow: again prevention is better than treatment.
    Niccoli G, Kharbanda RK, Crea F, et al. · Eur Heart J · 2011 · Background
    PubMed: PMID 20837571 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  10. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature.
    Nalysnyk L, Hernandez-Medina M, Krishnarajah G, et al. · Diabetes Obes Metab · 2011 · Background
    PubMed: PMID 20380649 · NCT04203927 (EJB051) · Insulin Resistance
  11. The pathogenesis of rheumatoid arthritis.
    McInnes IB, Schett G · N Engl J Med · 2011 · Background
    PubMed: PMID 22150039 · NCT06641128 · Arthritis, Rheumatoid
  12. Strong association between a new marker of hemolysis and glomerulopathy in sickle cell anemia.
    Maier-Redelsperger M, Lévy P, Lionnet F, et al. · Blood Cells Mol Dis · 2011 · Background
    PubMed: PMID 20833087 · NCT07175051 (EMPA-CKD) · Albuminuria
  13. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study.
    Mahfoud F, Schlaich M, Kindermann I, et al. · Circulation · 2011 · Background
    PubMed: PMID 21518978 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  14. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome.
    Lucero D, Zago V, López GI, et al. · Clin Chim Acta · 2011 · Background
    PubMed: PMID 20887718 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  15. Free fatty acids induce insulin resistance in both cardiac and skeletal muscle microvasculature in humans.
    Liu J, Jahn LA, Fowler DE, et al. · J Clin Endocrinol Metab · 2011 · Background
    PubMed: PMID 21047922 · NCT04203927 (EJB051) · Insulin Resistance
  16. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function.
    James MT, Ghali WA, Tonelli M, et al. · Kidney Int · 2011 · Background
    PubMed: PMID 20686453 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  17. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging.
    Inoue T, Kozawa E, Okada H, et al. · J Am Soc Nephrol · 2011 · Background
    PubMed: PMID 21757771 · NCT07175051 (EMPA-CKD) · Albuminuria
  18. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease.
    Gil-Bea FJ, Solas M, Solomon A, et al. · J Alzheimers Dis · 2011 · Background
    PubMed: PMID 20847404 · NCT05081219 · Alzheimer Disease
  19. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans.
    Chai W, Liu J, Jahn LA, et al. · Diabetes Care · 2011 · Background
    PubMed: PMID 21617098 · NCT04203927 (EJB051) · Insulin Resistance
  20. What is the right dose for children?
    Cella M, Knibbe C, Danhof M, et al. · Br J Clin Pharmacol · 2011 · Background
    PubMed: PMID 21087295 · NCT06012266 · Heart Failure
  21. Modelling and simulation as research tools in paediatric drug development.
    Bellanti F, Della Pasqua O · Eur J Clin Pharmacol · 2011 · Background
    PubMed: PMID 21246352 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  22. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.
    Baker LD, Cross DJ, Minoshima S, et al. · Arch Neurol · 2011 · Background
    PubMed: PMID 20837822 · NCT05081219 · Alzheimer Disease
  23. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ · Trends Pharmacol Sci · 2011 · Background
    PubMed: PMID 21211857 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  24. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia.
    Aygun B, Mortier NA, Smeltzer MP, et al. · Pediatr Nephrol · 2011 · Background
    PubMed: PMID 21559933 · NCT07175051 (EMPA-CKD) · Albuminuria
  25. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
    Abdul-Ghani MA, Norton L, Defronzo RA, et al. · Endocr Rev · 2011 · Background
    PubMed: PMID 21606218 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2

2010 (16 papers)

  1. Neuronal dynamics and axonal flow, ii. The olfactory nerve as model test object.
    Weiss P, Holland Y · Proc Natl Acad Sci U S A · 2010 · Background
    PubMed: PMID 16591462 · NCT05081219 · Alzheimer Disease
  2. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.
    Ware RE, Rees RC, Sarnaik SA, et al. · J Pediatr · 2010 · Background
    PubMed: PMID 19880138 · NCT07175051 (EMPA-CKD) · Albuminuria
  3. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
    von Eynatten M, Baumann M, Heemann U, et al. · Eur J Clin Invest · 2010 · Background
    PubMed: PMID 19912308 · NCT07175051 (EMPA-CKD) · Albuminuria
  4. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, et al. · Dig Liver Dis · 2010 · Background
    PubMed: PMID 20207596 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  5. The global burden of diabetes and its complications: an emerging pandemic.
    van Dieren S, Beulens JW, van der Schouw YT, et al. · Eur J Cardiovasc Prev Rehabil · 2010 · Background
    PubMed: PMID 20489418 · NCT04131582 (4T) · Insulin Resistance
  6. Assessment of renal fibrosis with diffusion-weighted MR imaging: study with murine model of unilateral ureteral obstruction.
    Togao O, Doi S, Kuro-o M, et al. · Radiology · 2010 · Background
    PubMed: PMID 20406881 · NCT07175051 (EMPA-CKD) · Albuminuria
  7. Muscle sympathetic nerve activity is related to a surrogate marker of endothelial function in healthy individuals.
    Sverrisdóttir YB, Jansson LM, Hägg U, et al. · PLoS One · 2010 · Background
    PubMed: PMID 20174639 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  8. The diagnosis of urinary tract infection: a systematic review.
    Schmiemann G, Kniehl E, Gebhardt K, et al. · Dtsch Arztebl Int · 2010 · Background
    PubMed: PMID 20539810 · NCT04735042 (UTI-flog) · Diabetes Mellitus, Type 2
  9. Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome.
    Ritt M, Janka R, Schneider MP, et al. · Nephrol Dial Transplant · 2010 · Background
    PubMed: PMID 19934080 · NCT07175051 (EMPA-CKD) · Albuminuria
  10. Improved survival of children and adolescents with sickle cell disease.
    Quinn CT, Rogers ZR, McCavit TL, et al. · Blood · 2010 · Background
    PubMed: PMID 20194891 · NCT07175051 (EMPA-CKD) · Albuminuria
  11. Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists.
    Kielgast U, Holst JJ, Madsbad S, et al. · Curr Diabetes Rev · 2010 · Background
    PubMed: PMID 19925391 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  12. Lactate dehydrogenase as a predictor of kidney involvement in patients with sickle cell anemia.
    Gurkan S, Scarponi KJ, Hotchkiss H, et al. · Pediatr Nephrol · 2010 · Background
    PubMed: PMID 20517617 · NCT07175051 (EMPA-CKD) · Albuminuria
  13. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
    Fakhoury WK, Lereun C, Wright D, et al. · Pharmacology · 2010 · Background
    PubMed: PMID 20616619 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  14. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.
    Drucker DJ, Sherman SI, Gorelick FS, et al. · Diabetes Care · 2010 · Background
    PubMed: PMID 20103558 · NCT04131582 (4T) · Insulin Resistance
  15. Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
    Chai W, Wang W, Liu J, et al. · Hypertension · 2010 · Background
    PubMed: PMID 19996061 · NCT04203927 (EJB051) · Insulin Resistance
  16. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease.
    Becton LJ, Kalpatthi RV, Rackoff E, et al. · Pediatr Nephrol · 2010 · Background
    PubMed: PMID 20505954 · NCT07175051 (EMPA-CKD) · Albuminuria

2009 (17 papers)

  1. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.
    Moghissi ES, Korytkowski MT, DiNardo M, et al. · Diabetes Care · 2009 · Trial result
    PubMed: PMID 19429873 · NCT06187285 · Diabetes Mellitus, Type 2
  2. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.
    Zhao WQ, Townsend M · Biochim Biophys Acta · 2009 · Background
    PubMed: PMID 19026743 · NCT05081219 · Alzheimer Disease
  3. Seizure suppression via glycolysis inhibition with 2-deoxy-D-glucose (2DG).
    Stafstrom CE, Roopra A, Sutula TP, et al. · Epilepsia · 2009 · Background
    PubMed: PMID 19049601 · NCT05512130 · Epilepsy
  4. Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models.
    Stafstrom CE, Ockuly JC, Murphree L, et al. · Ann Neurol · 2009 · Background
    PubMed: PMID 19399874 · NCT05512130 · Epilepsy
  5. The ketogenic diet in a pill: is this possible?
    Rho JM, Sankar R · Epilepsia · 2009 · Background
    PubMed: PMID 19049610 · NCT05512130 · Epilepsy
  6. Myocardial no-reflow in humans.
    Niccoli G, Burzotta F, Galiuto L, et al. · J Am Coll Cardiol · 2009 · Background
    PubMed: PMID 19608025 · NCT06342141 (EMPA-PCI) · No-Reflow Phenomenon
  7. A new equation to estimate glomerular filtration rate.
    Levey AS, Stevens LA, Schmid CH, et al. · Ann Intern Med · 2009 · Background
    PubMed: PMID 19414839 · NCT06473844 · Inflammation
  8. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation.
    Lee CC, Kuo YM, Huang CC, et al. · Neurobiol Aging · 2009 · Background
    PubMed: PMID 17692997 · NCT05081219 · Alzheimer Disease
  9. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.
    Haase M, Bellomo R, Devarajan P, et al. · Am J Kidney Dis · 2009 · Background
    PubMed: PMID 19850388 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  10. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.
    Francis GJ, Martinez JA, Liu WQ, et al. · Brain · 2009 · Background
    PubMed: PMID 19015157 · NCT05081219 · Alzheimer Disease
  11. Insulin resistance versus beta-cell dysfunction in the pathogenesis of type 2 diabetes.
    Ferrannini E · Curr Diab Rep · 2009 · Background
    PubMed: PMID 19490819 · NCT04131582 (4T) · Insulin Resistance
  12. Epidemiology of diabetes and diabetes-related complications.
    Deshpande AD, Harris-Hayes M, Schootman M, et al. · Phys Ther · 2009 · Background
    PubMed: PMID 18801858 · NCT05359432 · Diabetes Mellitus, Type 2
  13. Actos Now for the prevention of diabetes (ACT NOW) study.
    Defronzo RA, Banerji M, Bray GA, et al. · BMC Endocr Disord · 2009 · Background
    PubMed: PMID 19640291 · NCT04131582 (4T) · Insulin Resistance
  14. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.
    De Felice FG, Vieira MN, Bomfim TR, et al. · Proc Natl Acad Sci U S A · 2009 · Background
    PubMed: PMID 19188609 · NCT05081219 · Alzheimer Disease
  15. Influence of resistance and aerobic exercise on hunger, circulating levels of acylated ghrelin, and peptide YY in healthy males.
    Broom DR, Batterham RL, King JA, et al. · Am J Physiol Regul Integr Comp Physiol · 2009 · Background
    PubMed: PMID 18987287 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  16. A syndrome with congenital neutropenia and mutations in G6PC3.
    Boztug K, Appaswamy G, Ashikov A, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19118303 · NCT05078879 · Crohn Disease
  17. Cardiorenal risk prevalence in sickle cell hemoglobinopathy.
    Abo-Zenah H, Moharram M, El Nahas AM, et al. · Nephron Clin Pract · 2009 · Background
    PubMed: PMID 19390209 · NCT07175051 (EMPA-CKD) · Albuminuria

2008 (17 papers)

  1. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.
    Williams ES, Shah SJ, Ali S, et al. · Eur J Heart Fail · 2008 · Background
    PubMed: PMID 18160340 · NCT05911724 · Heart Failure
  2. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.
    Townsend M, Mehta T, Selkoe DJ, et al. · J Biol Chem · 2008 · Background
    PubMed: PMID 17855343 · NCT05081219 · Alzheimer Disease
  3. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.
    Selkoe DJ · Behav Brain Res · 2008 · Background
    PubMed: PMID 18359102 · NCT05081219 · Alzheimer Disease
  4. Cardiorenal syndrome.
    Ronco C, Haapio M, House AA, et al. · J Am Coll Cardiol · 2008 · Background
    PubMed: PMID 19007588 · NCT06249945 (EMPA-PRED) · Heart Failure
  5. Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
    Reger MA, Watson GS, Green PS, et al. · Neurology · 2008 · Background
    PubMed: PMID 17942819 · NCT05081219 · Alzheimer Disease
  6. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
    Reger MA, Watson GS, Green PS, et al. · J Alzheimers Dis · 2008 · Background
    PubMed: PMID 18430999 · NCT05081219 · Alzheimer Disease
  7. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R, Del Prato S · Diabetes Metab · 2008 · Background
    PubMed: PMID 18640587 · NCT04131582 (4T) · Insulin Resistance
  8. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography.
    Ling W, Zhaohui N, Ben H, et al. · Nephron Clin Pract · 2008 · Background
    PubMed: PMID 18287807 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  9. Blood oxygen level-dependent MR imaging of the kidneys.
    Li LP, Halter S, Prasad PV, et al. · Magn Reson Imaging Clin N Am · 2008 · Background
    PubMed: PMID 18926426 · NCT07175051 (EMPA-CKD) · Albuminuria
  10. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.
    Hartog JW, Voors AA, Bakker SJ, et al. · Eur J Heart Fail · 2008 · Background
    PubMed: PMID 18023248 · NCT03151343 (SIMPLE)
  11. Obese men respond to cognitive but not to catabolic brain insulin signaling.
    Hallschmid M, Benedict C, Schultes B, et al. · Int J Obes (Lond) · 2008 · Background
    PubMed: PMID 17848936 · NCT05081219 · Alzheimer Disease
  12. European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population.
    Eur J Health Law · 2008 · Background
    PubMed: PMID 18988606 · NCT06012266 · Heart Failure
  13. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo.
    Chiu SL, Chen CM, Cline HT, et al. · Neuron · 2008 · Background
    PubMed: PMID 18549783 · NCT05081219 · Alzheimer Disease
  14. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.
    Bernstein CN, Wajda A, Blanchard JF, et al. · Clin Gastroenterol Hepatol · 2008 · Background
    PubMed: PMID 18063423 · NCT05610956 · Colitis, Ulcerative
  15. Pediatric antihypertensive trial failures: analysis of end points and dose range.
    Benjamin DK, Smith PB, Jadhav P, et al. · Hypertension · 2008 · Background
    PubMed: PMID 18332283 · NCT06012266 · Heart Failure
  16. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin.
    Benedict C, Kern W, Schultes B, et al. · J Clin Endocrinol Metab · 2008 · Background
    PubMed: PMID 18230654 · NCT05081219 · Alzheimer Disease
  17. Short-term follow-up of patients with sickle cell disease and albuminuria.
    Alvarez O, Lopez-Mitnik G, Zilleruelo G, et al. · Pediatr Blood Cancer · 2008 · Background
    PubMed: PMID 18293385 · NCT07175051 (EMPA-CKD) · Albuminuria

2007 (8 papers)

  1. Protective effects of carvedilol against anthracycline-induced cardiomyopathy.
    Kalay N, Basar E, Ozdogru I, et al. · J Am Coll Cardiol · 2007 · Trial result
    PubMed: PMID 17161256 · NCT06103279 · Neoplasms
  2. Psychosocial and non-psychosocial risk factors for the new diagnosis of diabetes in elderly women.
    Strodl E, Kenardy J · Diabetes Res Clin Pract · 2007 · Background
    PubMed: PMID 16584801 · NCT05359432 · Diabetes Mellitus, Type 2
  3. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.
    Retnakaran R, Cull CA, Thorne KI, et al. · Diabetes · 2007 · Background
    PubMed: PMID 16731850 · NCT04215445 · Diabetes Mellitus
  4. Acute decrease in renal microvascular PO2 during acute normovolemic hemodilution.
    Johannes T, Mik EG, Nohé B, et al. · Am J Physiol Renal Physiol · 2007 · Background
    PubMed: PMID 17077389 · NCT07175051 (EMPA-CKD) · Albuminuria
  5. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease.
    Hueb W, Gersh BJ, Costa F, et al. · Ann Thorac Surg · 2007 · Background
    PubMed: PMID 17184637 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  6. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.
    Dunning BE, Gerich JE · Endocr Rev · 2007 · Background
    PubMed: PMID 17409288 · NCT04131582 (4T) · Insulin Resistance
  7. Diabetes and mortality following acute coronary syndromes.
    Donahoe SM, Stewart GC, McCabe CH, et al. · JAMA · 2007 · Background
    PubMed: PMID 17699010 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  8. Will 3-dimensional PET-CT enable the routine quantification of myocardial blood flow?
    deKemp RA, Yoshinaga K, Beanlands RS, et al. · J Nucl Cardiol · 2007 · Background
    PubMed: PMID 17556173 · NCT03151343 (SIMPLE)

2006 (16 papers)

  1. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients.
    Zimmerman JE, Kramer AA, McNair DS, et al. · Crit Care Med · 2006 · Background
    PubMed: PMID 16540951 · NCT06473844 · Inflammation
  2. Incidence, causes, and outcomes of dilated cardiomyopathy in children.
    Towbin JA, Lowe AM, Colan SD, et al. · JAMA · 2006 · Background
    PubMed: PMID 17047217 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  3. A brief measure for assessing generalized anxiety disorder: the GAD-7.
    Spitzer RL, Kroenke K, Williams JB, et al. · Arch Intern Med · 2006 · Background
    PubMed: PMID 16717171 · NCT05081219 · Alzheimer Disease
  4. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients.
    Scognamiglio R, Negut C, De Kreutzenberg SV, et al. · Circulation · 2006 · Background
    PubMed: PMID 15998667 · NCT04203927 (EJB051) · Insulin Resistance
  5. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine.
    Rivera EJ, Goldin A, Fulmer N, et al. · J Alzheimers Dis · 2006 · Background
    PubMed: PMID 16340083 · NCT05081219 · Alzheimer Disease
  6. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.
    Reger MA, Watson GS, Frey WH, et al. · Neurobiol Aging · 2006 · Background
    PubMed: PMID 15964100 · NCT05081219 · Alzheimer Disease
  7. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
    Rahmoune H, Thompson PW, Ward JM, et al. · Diabetes · 2006 · Background
    PubMed: PMID 16306358 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2
  8. Evaluation of intra-renal oxygenation by BOLD MRI.
    Prasad PV · Nephron Clin Pract · 2006 · Background
    PubMed: PMID 16543757 · NCT07175051 (EMPA-CKD) · Albuminuria
  9. Low-glycemic-index treatment: a liberalized ketogenic diet for treatment of intractable epilepsy.
    Pfeifer HH, Thiele EA · Neurology · 2006 · Background
    PubMed: PMID 16344529 · NCT05512130 · Epilepsy
  10. Contrast-induced nephropathy: definition, epidemiology, and patients at risk.
    Mehran R, Nikolsky E · Kidney Int Suppl · 2006 · Background
    PubMed: PMID 16612394 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  11. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application.
    Kovatchev BP, Clarke WL, Breton M, et al. · Diabetes Technol Ther · 2006 · Background
    PubMed: PMID 16386091 · NCT04203927 (EJB051) · Insulin Resistance
  12. Endothelial Na+-D-glucose cotransporter: no role in insulin-mediated glucose uptake.
    Kolka CM, Rattigan S, Richards SM, et al. · Horm Metab Res · 2006 · Background
    PubMed: PMID 16308832 · NCT04203927 (EJB051) · Insulin Resistance
  13. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure.
    Guasch A, Navarrete J, Nass K, et al. · J Am Soc Nephrol · 2006 · Background
    PubMed: PMID 16837635 · NCT07175051 (EMPA-CKD) · Albuminuria
  14. Mechanisms of sympathetic activation in obesity-related hypertension.
    Esler M, Straznicky N, Eikelis N, et al. · Hypertension · 2006 · Background
    PubMed: PMID 17000932 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  15. The precuneus: a review of its functional anatomy and behavioural correlates.
    Cavanna AE, Trimble MR · Brain · 2006 · Background
    PubMed: PMID 16399806 · NCT05081219 · Alzheimer Disease
  16. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
    Belfort R, Harrison SA, Brown K, et al. · N Engl J Med · 2006 · Background
    PubMed: PMID 17135584 · NCT05605158 · Non-alcoholic Fatty Liver Disease

2005 (11 papers)

  1. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation.
    Cosio FG, Kudva Y, van der Velde M, et al. · Kidney Int · 2005 · Trial result
    PubMed: PMID 15882287 · NCT06095492 (EmLinaRenal) · Diabetes Mellitus
  2. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
    Zhao L, Teter B, Morihara T, et al. · J Neurosci · 2005 · Background
    PubMed: PMID 15590928 · NCT05081219 · Alzheimer Disease
  3. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans.
    Stockhorst U, de Fries D, Steingrueber HJ, et al. · Physiol Behav · 2005 · Background
    PubMed: PMID 15501490 · NCT05081219 · Alzheimer Disease
  4. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart.
    Sharma S, Adrogue JV, Golfman L, et al. · FASEB J · 2005 · Background
    PubMed: PMID 15522914 · NCT03151343 (SIMPLE)
  5. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients.
    Powars DR, Chan LS, Hiti A, et al. · Medicine (Baltimore) · 2005 · Background
    PubMed: PMID 16267411 · NCT07175051 (EMPA-CKD) · Albuminuria
  6. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA, El-Ouaghlidi A, Gabrys B, et al. · Regul Pept · 2005 · Background
    PubMed: PMID 15491793 · NCT04131582 (4T) · Insulin Resistance
  7. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Kleiner DE, Brunt EM, Van Natta M, et al. · Hepatology · 2005 · Background
    PubMed: PMID 15915461 · NCT02964715 · Non-alcoholic Fatty Liver Disease
  8. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults.
    Fishel MA, Watson GS, Montine TJ, et al. · Arch Neurol · 2005 · Background
    PubMed: PMID 16216936 · NCT05081219 · Alzheimer Disease
  9. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
    de Zeeuw D, Remuzzi G, Parving HH, et al. · Circulation · 2005 · Background
    PubMed: PMID 15302780 · NCT07175051 (EMPA-CKD) · Albuminuria
  10. The relationship between microalbuminuria and glomerular filtration rate in young type 1 diabetic subjects: The Oxford Regional Prospective Study.
    Amin R, Turner C, van Aken S, et al. · Kidney Int · 2005 · Background
    PubMed: PMID 16164650 · NCT07175051 (EMPA-CKD) · Albuminuria
  11. Diagnosis and classification of diabetes mellitus.
    American Diabetes Association · Diabetes Care · 2005 · Background
    PubMed: PMID 15618111 · NCT05359432 · Diabetes Mellitus, Type 2

2004 (8 papers)

  1. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial.
    Vaccaro O, Eberly LE, Neaton JD, et al. · Arch Intern Med · 2004 · Background
    PubMed: PMID 15249353 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  2. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.
    Thorne RG, Pronk GJ, Padmanabhan V, et al. · Neuroscience · 2004 · Background
    PubMed: PMID 15262337 · NCT05081219 · Alzheimer Disease
  3. FAIR true-FISP perfusion imaging of the kidneys.
    Martirosian P, Klose U, Mader I, et al. · Magn Reson Med · 2004 · Background
    PubMed: PMID 14755661 · NCT07175051 (EMPA-CKD) · Albuminuria
  4. Intranasally administered insulin intended for prevention of type 1 diabetes--a safety study in healthy adults.
    Kupila A, Sipilä J, Keskinen P, et al. · Diabetes Metab Res Rev · 2004 · Background
    PubMed: PMID 12951650 · NCT05081219 · Alzheimer Disease
  5. Efficacy of the Atkins diet as therapy for intractable epilepsy.
    Kossoff EH, Krauss GL, McGrogan JR, et al. · Neurology · 2004 · Background
    PubMed: PMID 14694049 · NCT05512130 · Epilepsy
  6. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study.
    Gastaldelli A, Ferrannini E, Miyazaki Y, et al. · Diabetologia · 2004 · Background
    PubMed: PMID 14666364 · NCT04131582 (4T) · Insulin Resistance
  7. Insulin and neurodegenerative disease: shared and specific mechanisms.
    Craft S, Watson GS · Lancet Neurol · 2004 · Background
    PubMed: PMID 14980532 · NCT05081219 · Alzheimer Disease
  8. Intranasal insulin improves memory in humans.
    Benedict C, Hallschmid M, Hatke A, et al. · Psychoneuroendocrinology · 2004 · Background
    PubMed: PMID 15288712 · NCT05081219 · Alzheimer Disease

2003 (5 papers)

  1. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy.
    Schlaich MP, Kaye DM, Lambert E, et al. · Circulation · 2003 · Background
    PubMed: PMID 12847071 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  2. Cardiomyopathy in muscular dystrophies.
    Muntoni F · Curr Opin Neurol · 2003 · Background
    PubMed: PMID 14501841 · NCT06643442 (REDMeD) · Dmd-Associated Dilated Cardiomyopathy
  3. Nasal drug delivery: new developments and strategies.
    Illum L · Drug Discov Today · 2003 · Background
    PubMed: PMID 12547019 · NCT05081219 · Alzheimer Disease
  4. Impact of the obesity epidemic on hypertension and renal disease.
    Hall JE, Jones DW, Kuo JJ, et al. · Curr Hypertens Rep · 2003 · Background
    PubMed: PMID 12948431 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  5. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
    Butler AE, Janson J, Bonner-Weir S, et al. · Diabetes · 2003 · Background
    PubMed: PMID 12502499 · NCT04131582 (4T) · Insulin Resistance

2002 (12 papers)

  1. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke.
    Williams LS, Rotich J, Qi R, et al. · Neurology · 2002 · Trial result
    PubMed: PMID 12105309 · NCT06187285 · Diabetes Mellitus, Type 2
  2. Intensive insulin therapy in critically ill patients.
    van den Berghe G, Wouters P, Weekers F, et al. · N Engl J Med · 2002 · Trial result
    PubMed: PMID 11794168 · NCT06187285 · Diabetes Mellitus, Type 2
  3. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.
    Umpierrez GE, Isaacs SD, Bazargan N, et al. · J Clin Endocrinol Metab · 2002 · Trial result
    PubMed: PMID 11889147 · NCT06187285 · Diabetes Mellitus, Type 2
  4. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT, Bakris G, Greene T, et al. · JAMA · 2002 · Background
    PubMed: PMID 12435255 · NCT07175051 (EMPA-CKD) · Albuminuria
  5. Early goal-directed therapy in the treatment of severe sepsis and septic shock.
    Rivers E, Nguyen B, Havstad S, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11794169 · NCT06473844 · Inflammation
  6. Current concepts in mild cognitive impairment.
    Petersen RC, Doody R, Kurz A, et al. · Arch Neurol · 2002 · Background
    PubMed: PMID 11735772 · NCT05081219 · Alzheimer Disease
  7. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance.
    Iozzo P, Chareonthaitawee P, Dutka D, et al. · Diabetes · 2002 · Background
    PubMed: PMID 12351442 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  8. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.
    Hasegawa T, Yoneda M, Nakamura K, et al. · Aliment Pharmacol Ther · 2002 · Background
    PubMed: PMID 11564008 · NCT05605158 · Non-alcoholic Fatty Liver Disease
  9. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III.
    Garg AX, Kiberd BA, Clark WF, et al. · Kidney Int · 2002 · Background
    PubMed: PMID 12028457 · NCT04215445 · Diabetes Mellitus
  10. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.
    Cerqueira MD, Weissman NJ, Dilsizian V, et al. · Circulation · 2002 · Background
    PubMed: PMID 11815441 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  11. Sniffing neuropeptides: a transnasal approach to the human brain.
    Born J, Lange T, Kern W, et al. · Nat Neurosci · 2002 · Background
    PubMed: PMID 11992114 · NCT05081219 · Alzheimer Disease
  12. History of diabetes mellitus.
    Ahmed AM · Saudi Med J · 2002 · Background
    PubMed: PMID 11953758 · NCT07452913 · Diabetes Mellitus, Type 2

2001 (9 papers)

  1. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview.
    Capes SE, Hunt D, Malmberg K, et al. · Stroke · 2001 · Trial result
    PubMed: PMID 11588337 · NCT06187285 · Diabetes Mellitus, Type 2
  2. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study.
    Wierenga KJ, Hambleton IR, Lewis NA, et al. · Lancet · 2001 · Background
    PubMed: PMID 11247552 · NCT07175051 (EMPA-CKD) · Albuminuria
  3. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
    Tuomilehto J, Lindström J, Eriksson JG, et al. · N Engl J Med · 2001 · Background
    PubMed: PMID 11333990 · NCT04131582 (4T) · Insulin Resistance
  4. The PHQ-9: validity of a brief depression severity measure.
    Kroenke K, Spitzer RL, Williams JB, et al. · J Gen Intern Med · 2001 · Background
    PubMed: PMID 11556941 · NCT05081219 · Alzheimer Disease
  5. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability.
    Gerber BL, Ordoubadi FF, Wijns W, et al. · Eur Heart J · 2001 · Background
    PubMed: PMID 11511119 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  6. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.
    Gasparini L, Gouras GK, Wang R, et al. · J Neurosci · 2001 · Background
    PubMed: PMID 11306609 · NCT05081219 · Alzheimer Disease
  7. On sample size calculation in bioequivalence trials.
    Chow SC, Wang H · J Pharmacokinet Pharmacodyn · 2001 · Background
    PubMed: PMID 11381568 · NCT05132023
  8. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
    Brenner BM, Cooper ME, de Zeeuw D, et al. · N Engl J Med · 2001 · Background
    PubMed: PMID 11565518 · NCT07175051 (EMPA-CKD) · Albuminuria
  9. [Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population].
    Ascaso JF, Romero P, Real JT, et al. · Med Clin (Barc) · 2001 · Background
    PubMed: PMID 11707218 · NCT04131582 (4T) · Insulin Resistance

2000 (2 papers)

  1. Oxidative stress in anemia.
    Grune T, Sommerburg O, Siems WG, et al. · Clin Nephrol · 2000 · Background
    PubMed: PMID 10746801 · NCT07175051 (EMPA-CKD) · Albuminuria
  2. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
    Gasche C, Scholmerich J, Brynskov J, et al. · Inflamm Bowel Dis · 2000 · Background
    PubMed: PMID 10701144 · NCT05610956 · Colitis, Ulcerative

1999 (4 papers)

  1. Nephropathy in patients with type 2 diabetes mellitus.
    Ritz E, Orth SR · N Engl J Med · 1999 · Background
    PubMed: PMID 10511612 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2
  2. Central nervous system effects of intranasally administered insulin during euglycemia in men.
    Kern W, Born J, Schreiber H, et al. · Diabetes · 1999 · Background
    PubMed: PMID 10078556 · NCT05081219 · Alzheimer Disease
  3. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.
    Gutzwiller JP, Drewe J, Göke B, et al. · Am J Physiol · 1999 · Background
    PubMed: PMID 10233049 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  4. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group.
    Cordonnier DJ, Pinel N, Barro C, et al. · J Am Soc Nephrol · 1999 · Background
    PubMed: PMID 10361863 · NCT03173963 · Diabetes Mellitus, Type 2

1998 (10 papers)

  1. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients.
    Pomposelli JJ, Baxter JK, Babineau TJ, et al. · JPEN J Parenter Enteral Nutr · 1998 · Trial result
    PubMed: PMID 9527963 · NCT06187285 · Diabetes Mellitus, Type 2
  2. Effect of glycaemic control on myocardial sympathetic innervation assessed by [123I]metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients.
    Ziegler D, Weise F, Langen KJ, et al. · Diabetologia · 1998 · Background
    PubMed: PMID 9562349 · NCT03912909 (EMPA-SNS) · Diabetes Mellitus, Type 2
  3. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease.
    MacDermott RP, Sanderson IR, Reinecker HC, et al. · Inflamm Bowel Dis · 1998 · Background
    PubMed: PMID 9552229 · NCT05610956 · Colitis, Ulcerative
  4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet · 1998 · Background
    PubMed: PMID 9742976 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  5. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
    Haffner SM, Lehto S, Rönnemaa T, et al. · N Engl J Med · 1998 · Background
    PubMed: PMID 9673301 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  6. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease.
    Frölich L, Blum-Degen D, Bernstein HG, et al. · J Neural Transm (Vienna) · 1998 · Background
    PubMed: PMID 9720972 · NCT05081219 · Alzheimer Disease
  7. A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia.
    Foucan L, Bourhis V, Bangou J, et al. · Am J Med · 1998 · Background
    PubMed: PMID 9576406 · NCT07175051 (EMPA-CKD) · Albuminuria
  8. Prevalence of microalbuminuria in children with sickle cell disease.
    Dharnidharka VR, Dabbagh S, Atiyeh B, et al. · Pediatr Nephrol · 1998 · Background
    PubMed: PMID 9745872 · NCT07175051 (EMPA-CKD) · Albuminuria
  9. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype.
    Craft S, Peskind E, Schwartz MW, et al. · Neurology · 1998 · Background
    PubMed: PMID 9443474 · NCT05081219 · Alzheimer Disease
  10. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes.
    Ahrén B · Bioessays · 1998 · Background
    PubMed: PMID 9780839 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1

1997 (10 papers)

  1. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet · 1997 · Background
    PubMed: PMID 9217756 · NCT07175051 (EMPA-CKD) · Albuminuria
  2. Noninvasive comprehensive characterization of renal artery stenosis by combination of STAR angiography and EPISTAR perfusion imaging.
    Prasad PV, Kim D, Kaiser AM, et al. · Magn Reson Med · 1997 · Background
    PubMed: PMID 9358452 · NCT07175051 (EMPA-CKD) · Albuminuria
  3. Noninvasive evaluation of intrarenal oxygenation with BOLD MRI.
    Prasad PV, Edelman RR, Epstein FH, et al. · Circulation · 1997 · Background
    PubMed: PMID 8989140 · NCT07175051 (EMPA-CKD) · Albuminuria
  4. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
    Pan XR, Li GW, Hu YH, et al. · Diabetes Care · 1997 · Background
    PubMed: PMID 9096977 · NCT04131582 (4T) · Insulin Resistance
  5. Simple method to quantify myocardial glucose metabolism from MB ratio in myocardial FDG PET.
    Nishikawa J, Ohtake T, Yokoyama I, et al. · Ann Nucl Med · 1997 · Background
    PubMed: PMID 8883708 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  6. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA, Holst JJ, Willms B, et al. · Exp Clin Endocrinol Diabetes · 1997 · Background
    PubMed: PMID 9285204 · NCT06894784 (SEMPA) · Diabetes Mellitus, Type 1
  7. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience.
    Morris JC, Ernesto C, Schafer K, et al. · Neurology · 1997 · Background
    PubMed: PMID 9191756 · NCT05081219 · Alzheimer Disease
  8. The characterization of the nv-gvpACNOFGH gene cluster involved in gas vesicle formation in Natronobacterium vacuolatum.
    Mayr A, Pfeifer F · Arch Microbiol · 1997 · Background
    PubMed: PMID 9211710 · NCT07175051 (EMPA-CKD) · Albuminuria
  9. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons.
    Hong M, Lee VM · J Biol Chem · 1997 · Background
    PubMed: PMID 9235959 · NCT05081219 · Alzheimer Disease
  10. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Galasko D, Bennett D, Sano M, et al. · Alzheimer Dis Assoc Disord · 1997 · Background
    PubMed: PMID 9236950 · NCT05081219 · Alzheimer Disease

1996 (3 papers)

  1. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.
    Vincent JL, Moreno R, Takala J, et al. · Intensive Care Med · 1996 · Background
    PubMed: PMID 8844239 · NCT06473844 · Inflammation
  2. Quantitative analysis of the olfactory pathway for drug delivery to the brain.
    Thorne RG, Emory CR, Ala TA, et al. · Brain Res · 1996 · Background
    PubMed: PMID 8548316 · NCT05081219 · Alzheimer Disease
  3. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs.
    Sakane T, Akizuki M, Taki Y, et al. · J Pharm Pharmacol · 1996 · Background
    PubMed: PMID 7494186 · NCT05081219 · Alzheimer Disease

1995 (2 papers)

  1. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.
    Minoshima S, Frey KA, Foster NL, et al. · J Comput Assist Tomogr · 1995 · Background
    PubMed: PMID 7622680 · NCT05081219 · Alzheimer Disease
  2. Glycerol gluconeogenesis in fasting humans.
    Baba H, Zhang XJ, Wolfe RR, et al. · Nutrition · 1995 · Background
    PubMed: PMID 7647479 · NCT02833415 · Diabetes Mellitus

1994 (3 papers)

  1. Mortality in sickle cell disease. Life expectancy and risk factors for early death.
    Platt OS, Brambilla DJ, Rosse WF, et al. · N Engl J Med · 1994 · Background
    PubMed: PMID 7993409 · NCT07175051 (EMPA-CKD) · Albuminuria
  2. Anatomic standardization: linear scaling and nonlinear warping of functional brain images.
    Minoshima S, Koeppe RA, Frey KA, et al. · J Nucl Med · 1994 · Background
    PubMed: PMID 8071705 · NCT05081219 · Alzheimer Disease
  3. Increased renal metabolism in diabetes. Mechanism and functional implications.
    Körner A, Eklöf AC, Celsi G, et al. · Diabetes · 1994 · Background
    PubMed: PMID 8168637 · NCT05037695 (SAFE-PCI) · Diabetes Mellitus, Type 2

1993 (1 paper)

  1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
    Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. · N Engl J Med · 1993 · Background
    PubMed: PMID 8366922 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2

1992 (3 papers)

  1. A three-dimensional statistical analysis for CBF activation studies in human brain.
    Worsley KJ, Evans AC, Marrett S, et al. · J Cereb Blood Flow Metab · 1992 · Background
    PubMed: PMID 1400644 · NCT05081219 · Alzheimer Disease
  2. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study.
    Martin BC, Warram JH, Krolewski AS, et al. · Lancet · 1992 · Background
    PubMed: PMID 1357346 · NCT04131582 (4T) · Insulin Resistance
  3. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
    Enoki S, Mitsukawa T, Takemura J, et al. · Diabetes Res Clin Pract · 1992 · Background
    PubMed: PMID 1541241 · NCT04131582 (4T) · Insulin Resistance

1991 (2 papers)

  1. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality.
    Powars DR, Elliott-Mills DD, Chan L, et al. · Ann Intern Med · 1991 · Background
    PubMed: PMID 1892333 · NCT07175051 (EMPA-CKD) · Albuminuria
  2. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E, Hauschke D, Steinijans VW, et al. · Int J Clin Pharmacol Ther Toxicol · 1991 · Background
    PubMed: PMID 2004861 · NCT05132023

1990 (2 papers)

  1. Outcome of end-stage renal disease in patients with rare causes of renal failure. I. Inherited and metabolic disorders.
    Nissenson AR, Port FK · Q J Med · 1990 · Background
    PubMed: PMID 2516341 · NCT07175051 (EMPA-CKD) · Albuminuria
  2. A new predictive equation for resting energy expenditure in healthy individuals.
    Mifflin MD, St Jeor ST, Hill LA, et al. · Am J Clin Nutr · 1990 · Background
    PubMed: PMID 2305711 · NCT02798744 (SEESAW) · Diabetes Mellitus, Type 2

1988 (3 papers)

  1. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.
    Schuirmann DJ · J Pharmacokinet Biopharm · 1988 · Background
    PubMed: PMID 3450848 · NCT05132023
  2. Quantification of the glycolytic origin of plasma glycerol: implications for the use of the rate of appearance of plasma glycerol as an index of lipolysis in vivo.
    Nurjhan N, Kennedy F, Consoli A, et al. · Metabolism · 1988 · Background
    PubMed: PMID 3357420 · NCT02833415 · Diabetes Mellitus
  3. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.
    Le Bihan D, Breton E, Lallemand D, et al. · Radiology · 1988 · Background
    PubMed: PMID 3393671 · NCT07175051 (EMPA-CKD) · Albuminuria

1987 (1 paper)

  1. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey.
    Balin BJ, Broadwell RD, Salcman M, et al. · J Comp Neurol · 1987 · Background
    PubMed: PMID 3782501 · NCT05081219 · Alzheimer Disease

1986 (2 papers)

  1. Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo.
    Broadwell RD, Balin BJ · J Comp Neurol · 1986 · Background
    PubMed: PMID 2418083 · NCT05081219 · Alzheimer Disease
  2. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat.
    Baker H, Spencer RF · Exp Brain Res · 1986 · Background
    PubMed: PMID 3758265 · NCT05081219 · Alzheimer Disease

1985 (2 papers)

  1. Transport of molecules from nose to brain: transneuronal anterograde and retrograde labeling in the rat olfactory system by wheat germ agglutinin-horseradish peroxidase applied to the nasal epithelium.
    Shipley MT · Brain Res Bull · 1985 · Background
    PubMed: PMID 3840049 · NCT05081219 · Alzheimer Disease
  2. Outcome of toxic dilatation in ulcerative and Crohn's colitis.
    Greenstein AJ, Sachar DB, Gibas A, et al. · J Clin Gastroenterol · 1985 · Background
    PubMed: PMID 4008909 · NCT05610956 · Colitis, Ulcerative

1982 (3 papers)

  1. Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application.
    Reichek N, Wilson J, St John Sutton M, et al. · Circulation · 1982 · Background
    PubMed: PMID 7053293 · NCT05084235 · Heart Failure
  2. Insulin given intranasally induces hypoglycaemia in normal and diabetic subjects.
    Pontiroli AE, Alberetto M, Secchi A, et al. · Br Med J (Clin Res Ed) · 1982 · Background
    PubMed: PMID 6800439 · NCT05081219 · Alzheimer Disease
  3. A new clinical scale for the staging of dementia.
    Hughes CP, Berg L, Danziger WL, et al. · Br J Psychiatry · 1982 · Background
    PubMed: PMID 7104545 · NCT05081219 · Alzheimer Disease

1979 (2 papers)

  1. Diabetes and cardiovascular risk factors: the Framingham study.
    Kannel WB, McGee DL · Circulation · 1979 · Background
    PubMed: PMID 758126 · NCT04183868 (FIORE) · Diabetes Mellitus, Type 2
  2. Glucose clamp technique: a method for quantifying insulin secretion and resistance.
    DeFronzo RA, Tobin JD, Andres R, et al. · Am J Physiol · 1979 · Background
    PubMed: PMID 382871 · NCT04131582 (4T) · Insulin Resistance

1977 (1 paper)

  1. [Cariogenic properties of various snacks in animal experiments].
    Karle EJ, Gehring F, Trautner K, et al. · Dtsch Zahnarztl Z · 1977 · Background
    PubMed: PMID 269076 · NCT05610956 · Colitis, Ulcerative

1972 (1 paper)

  1. Uptake of exogenous proteins in mouse olfactory cells.
    Kristensson K, Olsson Y · Acta Neuropathol · 1972 · Background
    PubMed: PMID 5126829 · NCT05081219 · Alzheimer Disease

1969 (1 paper)

  1. An experience of ulcerative colitis. I. Toxic dilation in 55 cases.
    Jalan KN, Sircus W, Card WI, et al. · Gastroenterology · 1969 · Background
    PubMed: PMID 5305933 · NCT05610956 · Colitis, Ulcerative

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).